- Research article
- Open access
- Published: 04 June 2021
Coronavirus disease (COVID-19) pandemic: an overview of systematic reviews
- Israel Júnior Borges do Nascimento 1 , 2 ,
- Dónal P. O’Mathúna 3 , 4 ,
- Thilo Caspar von Groote 5 ,
- Hebatullah Mohamed Abdulazeem 6 ,
- Ishanka Weerasekara 7 , 8 ,
- Ana Marusic 9 ,
- Livia Puljak ORCID: orcid.org/0000-0002-8467-6061 10 ,
- Vinicius Tassoni Civile 11 ,
- Irena Zakarija-Grkovic 9 ,
- Tina Poklepovic Pericic 9 ,
- Alvaro Nagib Atallah 11 ,
- Santino Filoso 12 ,
- Nicola Luigi Bragazzi 13 &
- Milena Soriano Marcolino 1
On behalf of the International Network of Coronavirus Disease 2019 (InterNetCOVID-19)
BMC Infectious Diseases volume 21 , Article number: 525 ( 2021 ) Cite this article
19k Accesses
37 Citations
14 Altmetric
Metrics details
Navigating the rapidly growing body of scientific literature on the SARS-CoV-2 pandemic is challenging, and ongoing critical appraisal of this output is essential. We aimed to summarize and critically appraise systematic reviews of coronavirus disease (COVID-19) in humans that were available at the beginning of the pandemic.
Nine databases (Medline, EMBASE, Cochrane Library, CINAHL, Web of Sciences, PDQ-Evidence, WHO’s Global Research, LILACS, and Epistemonikos) were searched from December 1, 2019, to March 24, 2020. Systematic reviews analyzing primary studies of COVID-19 were included. Two authors independently undertook screening, selection, extraction (data on clinical symptoms, prevalence, pharmacological and non-pharmacological interventions, diagnostic test assessment, laboratory, and radiological findings), and quality assessment (AMSTAR 2). A meta-analysis was performed of the prevalence of clinical outcomes.
Eighteen systematic reviews were included; one was empty (did not identify any relevant study). Using AMSTAR 2, confidence in the results of all 18 reviews was rated as “critically low”. Identified symptoms of COVID-19 were (range values of point estimates): fever (82–95%), cough with or without sputum (58–72%), dyspnea (26–59%), myalgia or muscle fatigue (29–51%), sore throat (10–13%), headache (8–12%) and gastrointestinal complaints (5–9%). Severe symptoms were more common in men. Elevated C-reactive protein and lactate dehydrogenase, and slightly elevated aspartate and alanine aminotransferase, were commonly described. Thrombocytopenia and elevated levels of procalcitonin and cardiac troponin I were associated with severe disease. A frequent finding on chest imaging was uni- or bilateral multilobar ground-glass opacity. A single review investigated the impact of medication (chloroquine) but found no verifiable clinical data. All-cause mortality ranged from 0.3 to 13.9%.
Conclusions
In this overview of systematic reviews, we analyzed evidence from the first 18 systematic reviews that were published after the emergence of COVID-19. However, confidence in the results of all reviews was “critically low”. Thus, systematic reviews that were published early on in the pandemic were of questionable usefulness. Even during public health emergencies, studies and systematic reviews should adhere to established methodological standards.
Peer Review reports
The spread of the “Severe Acute Respiratory Coronavirus 2” (SARS-CoV-2), the causal agent of COVID-19, was characterized as a pandemic by the World Health Organization (WHO) in March 2020 and has triggered an international public health emergency [ 1 ]. The numbers of confirmed cases and deaths due to COVID-19 are rapidly escalating, counting in millions [ 2 ], causing massive economic strain, and escalating healthcare and public health expenses [ 3 , 4 ].
The research community has responded by publishing an impressive number of scientific reports related to COVID-19. The world was alerted to the new disease at the beginning of 2020 [ 1 ], and by mid-March 2020, more than 2000 articles had been published on COVID-19 in scholarly journals, with 25% of them containing original data [ 5 ]. The living map of COVID-19 evidence, curated by the Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-Centre), contained more than 40,000 records by February 2021 [ 6 ]. More than 100,000 records on PubMed were labeled as “SARS-CoV-2 literature, sequence, and clinical content” by February 2021 [ 7 ].
Due to publication speed, the research community has voiced concerns regarding the quality and reproducibility of evidence produced during the COVID-19 pandemic, warning of the potential damaging approach of “publish first, retract later” [ 8 ]. It appears that these concerns are not unfounded, as it has been reported that COVID-19 articles were overrepresented in the pool of retracted articles in 2020 [ 9 ]. These concerns about inadequate evidence are of major importance because they can lead to poor clinical practice and inappropriate policies [ 10 ].
Systematic reviews are a cornerstone of today’s evidence-informed decision-making. By synthesizing all relevant evidence regarding a particular topic, systematic reviews reflect the current scientific knowledge. Systematic reviews are considered to be at the highest level in the hierarchy of evidence and should be used to make informed decisions. However, with high numbers of systematic reviews of different scope and methodological quality being published, overviews of multiple systematic reviews that assess their methodological quality are essential [ 11 , 12 , 13 ]. An overview of systematic reviews helps identify and organize the literature and highlights areas of priority in decision-making.
In this overview of systematic reviews, we aimed to summarize and critically appraise systematic reviews of coronavirus disease (COVID-19) in humans that were available at the beginning of the pandemic.
Methodology
Research question.
This overview’s primary objective was to summarize and critically appraise systematic reviews that assessed any type of primary clinical data from patients infected with SARS-CoV-2. Our research question was purposefully broad because we wanted to analyze as many systematic reviews as possible that were available early following the COVID-19 outbreak.
Study design
We conducted an overview of systematic reviews. The idea for this overview originated in a protocol for a systematic review submitted to PROSPERO (CRD42020170623), which indicated a plan to conduct an overview.
Overviews of systematic reviews use explicit and systematic methods for searching and identifying multiple systematic reviews addressing related research questions in the same field to extract and analyze evidence across important outcomes. Overviews of systematic reviews are in principle similar to systematic reviews of interventions, but the unit of analysis is a systematic review [ 14 , 15 , 16 ].
We used the overview methodology instead of other evidence synthesis methods to allow us to collate and appraise multiple systematic reviews on this topic, and to extract and analyze their results across relevant topics [ 17 ]. The overview and meta-analysis of systematic reviews allowed us to investigate the methodological quality of included studies, summarize results, and identify specific areas of available or limited evidence, thereby strengthening the current understanding of this novel disease and guiding future research [ 13 ].
A reporting guideline for overviews of reviews is currently under development, i.e., Preferred Reporting Items for Overviews of Reviews (PRIOR) [ 18 ]. As the PRIOR checklist is still not published, this study was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 statement [ 19 ]. The methodology used in this review was adapted from the Cochrane Handbook for Systematic Reviews of Interventions and also followed established methodological considerations for analyzing existing systematic reviews [ 14 ].
Approval of a research ethics committee was not necessary as the study analyzed only publicly available articles.
Eligibility criteria
Systematic reviews were included if they analyzed primary data from patients infected with SARS-CoV-2 as confirmed by RT-PCR or another pre-specified diagnostic technique. Eligible reviews covered all topics related to COVID-19 including, but not limited to, those that reported clinical symptoms, diagnostic methods, therapeutic interventions, laboratory findings, or radiological results. Both full manuscripts and abbreviated versions, such as letters, were eligible.
No restrictions were imposed on the design of the primary studies included within the systematic reviews, the last search date, whether the review included meta-analyses or language. Reviews related to SARS-CoV-2 and other coronaviruses were eligible, but from those reviews, we analyzed only data related to SARS-CoV-2.
No consensus definition exists for a systematic review [ 20 ], and debates continue about the defining characteristics of a systematic review [ 21 ]. Cochrane’s guidance for overviews of reviews recommends setting pre-established criteria for making decisions around inclusion [ 14 ]. That is supported by a recent scoping review about guidance for overviews of systematic reviews [ 22 ].
Thus, for this study, we defined a systematic review as a research report which searched for primary research studies on a specific topic using an explicit search strategy, had a detailed description of the methods with explicit inclusion criteria provided, and provided a summary of the included studies either in narrative or quantitative format (such as a meta-analysis). Cochrane and non-Cochrane systematic reviews were considered eligible for inclusion, with or without meta-analysis, and regardless of the study design, language restriction and methodology of the included primary studies. To be eligible for inclusion, reviews had to be clearly analyzing data related to SARS-CoV-2 (associated or not with other viruses). We excluded narrative reviews without those characteristics as these are less likely to be replicable and are more prone to bias.
Scoping reviews and rapid reviews were eligible for inclusion in this overview if they met our pre-defined inclusion criteria noted above. We included reviews that addressed SARS-CoV-2 and other coronaviruses if they reported separate data regarding SARS-CoV-2.
Information sources
Nine databases were searched for eligible records published between December 1, 2019, and March 24, 2020: Cochrane Database of Systematic Reviews via Cochrane Library, PubMed, EMBASE, CINAHL (Cumulative Index to Nursing and Allied Health Literature), Web of Sciences, LILACS (Latin American and Caribbean Health Sciences Literature), PDQ-Evidence, WHO’s Global Research on Coronavirus Disease (COVID-19), and Epistemonikos.
The comprehensive search strategy for each database is provided in Additional file 1 and was designed and conducted in collaboration with an information specialist. All retrieved records were primarily processed in EndNote, where duplicates were removed, and records were then imported into the Covidence platform [ 23 ]. In addition to database searches, we screened reference lists of reviews included after screening records retrieved via databases.
Study selection
All searches, screening of titles and abstracts, and record selection, were performed independently by two investigators using the Covidence platform [ 23 ]. Articles deemed potentially eligible were retrieved for full-text screening carried out independently by two investigators. Discrepancies at all stages were resolved by consensus. During the screening, records published in languages other than English were translated by a native/fluent speaker.
Data collection process
We custom designed a data extraction table for this study, which was piloted by two authors independently. Data extraction was performed independently by two authors. Conflicts were resolved by consensus or by consulting a third researcher.
We extracted the following data: article identification data (authors’ name and journal of publication), search period, number of databases searched, population or settings considered, main results and outcomes observed, and number of participants. From Web of Science (Clarivate Analytics, Philadelphia, PA, USA), we extracted journal rank (quartile) and Journal Impact Factor (JIF).
We categorized the following as primary outcomes: all-cause mortality, need for and length of mechanical ventilation, length of hospitalization (in days), admission to intensive care unit (yes/no), and length of stay in the intensive care unit.
The following outcomes were categorized as exploratory: diagnostic methods used for detection of the virus, male to female ratio, clinical symptoms, pharmacological and non-pharmacological interventions, laboratory findings (full blood count, liver enzymes, C-reactive protein, d-dimer, albumin, lipid profile, serum electrolytes, blood vitamin levels, glucose levels, and any other important biomarkers), and radiological findings (using radiography, computed tomography, magnetic resonance imaging or ultrasound).
We also collected data on reporting guidelines and requirements for the publication of systematic reviews and meta-analyses from journal websites where included reviews were published.
Quality assessment in individual reviews
Two researchers independently assessed the reviews’ quality using the “A MeaSurement Tool to Assess Systematic Reviews 2 (AMSTAR 2)”. We acknowledge that the AMSTAR 2 was created as “a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions, or both” [ 24 ]. However, since AMSTAR 2 was designed for systematic reviews of intervention trials, and we included additional types of systematic reviews, we adjusted some AMSTAR 2 ratings and reported these in Additional file 2 .
Adherence to each item was rated as follows: yes, partial yes, no, or not applicable (such as when a meta-analysis was not conducted). The overall confidence in the results of the review is rated as “critically low”, “low”, “moderate” or “high”, according to the AMSTAR 2 guidance based on seven critical domains, which are items 2, 4, 7, 9, 11, 13, 15 as defined by AMSTAR 2 authors [ 24 ]. We reported our adherence ratings for transparency of our decision with accompanying explanations, for each item, in each included review.
One of the included systematic reviews was conducted by some members of this author team [ 25 ]. This review was initially assessed independently by two authors who were not co-authors of that review to prevent the risk of bias in assessing this study.
Synthesis of results
For data synthesis, we prepared a table summarizing each systematic review. Graphs illustrating the mortality rate and clinical symptoms were created. We then prepared a narrative summary of the methods, findings, study strengths, and limitations.
For analysis of the prevalence of clinical outcomes, we extracted data on the number of events and the total number of patients to perform proportional meta-analysis using RStudio© software, with the “meta” package (version 4.9–6), using the “metaprop” function for reviews that did not perform a meta-analysis, excluding case studies because of the absence of variance. For reviews that did not perform a meta-analysis, we presented pooled results of proportions with their respective confidence intervals (95%) by the inverse variance method with a random-effects model, using the DerSimonian-Laird estimator for τ 2 . We adjusted data using Freeman-Tukey double arcosen transformation. Confidence intervals were calculated using the Clopper-Pearson method for individual studies. We created forest plots using the RStudio© software, with the “metafor” package (version 2.1–0) and “forest” function.
Managing overlapping systematic reviews
Some of the included systematic reviews that address the same or similar research questions may include the same primary studies in overviews. Including such overlapping reviews may introduce bias when outcome data from the same primary study are included in the analyses of an overview multiple times. Thus, in summaries of evidence, multiple-counting of the same outcome data will give data from some primary studies too much influence [ 14 ]. In this overview, we did not exclude overlapping systematic reviews because, according to Cochrane’s guidance, it may be appropriate to include all relevant reviews’ results if the purpose of the overview is to present and describe the current body of evidence on a topic [ 14 ]. To avoid any bias in summary estimates associated with overlapping reviews, we generated forest plots showing data from individual systematic reviews, but the results were not pooled because some primary studies were included in multiple reviews.
Our search retrieved 1063 publications, of which 175 were duplicates. Most publications were excluded after the title and abstract analysis ( n = 860). Among the 28 studies selected for full-text screening, 10 were excluded for the reasons described in Additional file 3 , and 18 were included in the final analysis (Fig. 1 ) [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ]. Reference list screening did not retrieve any additional systematic reviews.
PRISMA flow diagram
Characteristics of included reviews
Summary features of 18 systematic reviews are presented in Table 1 . They were published in 14 different journals. Only four of these journals had specific requirements for systematic reviews (with or without meta-analysis): European Journal of Internal Medicine, Journal of Clinical Medicine, Ultrasound in Obstetrics and Gynecology, and Clinical Research in Cardiology . Two journals reported that they published only invited reviews ( Journal of Medical Virology and Clinica Chimica Acta ). Three systematic reviews in our study were published as letters; one was labeled as a scoping review and another as a rapid review (Table 2 ).
All reviews were published in English, in first quartile (Q1) journals, with JIF ranging from 1.692 to 6.062. One review was empty, meaning that its search did not identify any relevant studies; i.e., no primary studies were included [ 36 ]. The remaining 17 reviews included 269 unique studies; the majority ( N = 211; 78%) were included in only a single review included in our study (range: 1 to 12). Primary studies included in the reviews were published between December 2019 and March 18, 2020, and comprised case reports, case series, cohorts, and other observational studies. We found only one review that included randomized clinical trials [ 38 ]. In the included reviews, systematic literature searches were performed from 2019 (entire year) up to March 9, 2020. Ten systematic reviews included meta-analyses. The list of primary studies found in the included systematic reviews is shown in Additional file 4 , as well as the number of reviews in which each primary study was included.
Population and study designs
Most of the reviews analyzed data from patients with COVID-19 who developed pneumonia, acute respiratory distress syndrome (ARDS), or any other correlated complication. One review aimed to evaluate the effectiveness of using surgical masks on preventing transmission of the virus [ 36 ], one review was focused on pediatric patients [ 34 ], and one review investigated COVID-19 in pregnant women [ 37 ]. Most reviews assessed clinical symptoms, laboratory findings, or radiological results.
Systematic review findings
The summary of findings from individual reviews is shown in Table 2 . Overall, all-cause mortality ranged from 0.3 to 13.9% (Fig. 2 ).
A meta-analysis of the prevalence of mortality
Clinical symptoms
Seven reviews described the main clinical manifestations of COVID-19 [ 26 , 28 , 29 , 34 , 35 , 39 , 41 ]. Three of them provided only a narrative discussion of symptoms [ 26 , 34 , 35 ]. In the reviews that performed a statistical analysis of the incidence of different clinical symptoms, symptoms in patients with COVID-19 were (range values of point estimates): fever (82–95%), cough with or without sputum (58–72%), dyspnea (26–59%), myalgia or muscle fatigue (29–51%), sore throat (10–13%), headache (8–12%), gastrointestinal disorders, such as diarrhea, nausea or vomiting (5.0–9.0%), and others (including, in one study only: dizziness 12.1%) (Figs. 3 , 4 , 5 , 6 , 7 , 8 and 9 ). Three reviews assessed cough with and without sputum together; only one review assessed sputum production itself (28.5%).
A meta-analysis of the prevalence of fever
A meta-analysis of the prevalence of cough
A meta-analysis of the prevalence of dyspnea
A meta-analysis of the prevalence of fatigue or myalgia
A meta-analysis of the prevalence of headache
A meta-analysis of the prevalence of gastrointestinal disorders
A meta-analysis of the prevalence of sore throat
Diagnostic aspects
Three reviews described methodologies, protocols, and tools used for establishing the diagnosis of COVID-19 [ 26 , 34 , 38 ]. The use of respiratory swabs (nasal or pharyngeal) or blood specimens to assess the presence of SARS-CoV-2 nucleic acid using RT-PCR assays was the most commonly used diagnostic method mentioned in the included studies. These diagnostic tests have been widely used, but their precise sensitivity and specificity remain unknown. One review included a Chinese study with clinical diagnosis with no confirmation of SARS-CoV-2 infection (patients were diagnosed with COVID-19 if they presented with at least two symptoms suggestive of COVID-19, together with laboratory and chest radiography abnormalities) [ 34 ].
Therapeutic possibilities
Pharmacological and non-pharmacological interventions (supportive therapies) used in treating patients with COVID-19 were reported in five reviews [ 25 , 27 , 34 , 35 , 38 ]. Antivirals used empirically for COVID-19 treatment were reported in seven reviews [ 25 , 27 , 34 , 35 , 37 , 38 , 41 ]; most commonly used were protease inhibitors (lopinavir, ritonavir, darunavir), nucleoside reverse transcriptase inhibitor (tenofovir), nucleotide analogs (remdesivir, galidesivir, ganciclovir), and neuraminidase inhibitors (oseltamivir). Umifenovir, a membrane fusion inhibitor, was investigated in two studies [ 25 , 35 ]. Possible supportive interventions analyzed were different types of oxygen supplementation and breathing support (invasive or non-invasive ventilation) [ 25 ]. The use of antibiotics, both empirically and to treat secondary pneumonia, was reported in six studies [ 25 , 26 , 27 , 34 , 35 , 38 ]. One review specifically assessed evidence on the efficacy and safety of the anti-malaria drug chloroquine [ 27 ]. It identified 23 ongoing trials investigating the potential of chloroquine as a therapeutic option for COVID-19, but no verifiable clinical outcomes data. The use of mesenchymal stem cells, antifungals, and glucocorticoids were described in four reviews [ 25 , 34 , 35 , 38 ].
Laboratory and radiological findings
Of the 18 reviews included in this overview, eight analyzed laboratory parameters in patients with COVID-19 [ 25 , 29 , 30 , 32 , 33 , 34 , 35 , 39 ]; elevated C-reactive protein levels, associated with lymphocytopenia, elevated lactate dehydrogenase, as well as slightly elevated aspartate and alanine aminotransferase (AST, ALT) were commonly described in those eight reviews. Lippi et al. assessed cardiac troponin I (cTnI) [ 25 ], procalcitonin [ 32 ], and platelet count [ 33 ] in COVID-19 patients. Elevated levels of procalcitonin [ 32 ] and cTnI [ 30 ] were more likely to be associated with a severe disease course (requiring intensive care unit admission and intubation). Furthermore, thrombocytopenia was frequently observed in patients with complicated COVID-19 infections [ 33 ].
Chest imaging (chest radiography and/or computed tomography) features were assessed in six reviews, all of which described a frequent pattern of local or bilateral multilobar ground-glass opacity [ 25 , 34 , 35 , 39 , 40 , 41 ]. Those six reviews showed that septal thickening, bronchiectasis, pleural and cardiac effusions, halo signs, and pneumothorax were observed in patients suffering from COVID-19.
Quality of evidence in individual systematic reviews
Table 3 shows the detailed results of the quality assessment of 18 systematic reviews, including the assessment of individual items and summary assessment. A detailed explanation for each decision in each review is available in Additional file 5 .
Using AMSTAR 2 criteria, confidence in the results of all 18 reviews was rated as “critically low” (Table 3 ). Common methodological drawbacks were: omission of prospective protocol submission or publication; use of inappropriate search strategy: lack of independent and dual literature screening and data-extraction (or methodology unclear); absence of an explanation for heterogeneity among the studies included; lack of reasons for study exclusion (or rationale unclear).
Risk of bias assessment, based on a reported methodological tool, and quality of evidence appraisal, in line with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method, were reported only in one review [ 25 ]. Five reviews presented a table summarizing bias, using various risk of bias tools [ 25 , 29 , 39 , 40 , 41 ]. One review analyzed “study quality” [ 37 ]. One review mentioned the risk of bias assessment in the methodology but did not provide any related analysis [ 28 ].
This overview of systematic reviews analyzed the first 18 systematic reviews published after the onset of the COVID-19 pandemic, up to March 24, 2020, with primary studies involving more than 60,000 patients. Using AMSTAR-2, we judged that our confidence in all those reviews was “critically low”. Ten reviews included meta-analyses. The reviews presented data on clinical manifestations, laboratory and radiological findings, and interventions. We found no systematic reviews on the utility of diagnostic tests.
Symptoms were reported in seven reviews; most of the patients had a fever, cough, dyspnea, myalgia or muscle fatigue, and gastrointestinal disorders such as diarrhea, nausea, or vomiting. Olfactory dysfunction (anosmia or dysosmia) has been described in patients infected with COVID-19 [ 43 ]; however, this was not reported in any of the reviews included in this overview. During the SARS outbreak in 2002, there were reports of impairment of the sense of smell associated with the disease [ 44 , 45 ].
The reported mortality rates ranged from 0.3 to 14% in the included reviews. Mortality estimates are influenced by the transmissibility rate (basic reproduction number), availability of diagnostic tools, notification policies, asymptomatic presentations of the disease, resources for disease prevention and control, and treatment facilities; variability in the mortality rate fits the pattern of emerging infectious diseases [ 46 ]. Furthermore, the reported cases did not consider asymptomatic cases, mild cases where individuals have not sought medical treatment, and the fact that many countries had limited access to diagnostic tests or have implemented testing policies later than the others. Considering the lack of reviews assessing diagnostic testing (sensitivity, specificity, and predictive values of RT-PCT or immunoglobulin tests), and the preponderance of studies that assessed only symptomatic individuals, considerable imprecision around the calculated mortality rates existed in the early stage of the COVID-19 pandemic.
Few reviews included treatment data. Those reviews described studies considered to be at a very low level of evidence: usually small, retrospective studies with very heterogeneous populations. Seven reviews analyzed laboratory parameters; those reviews could have been useful for clinicians who attend patients suspected of COVID-19 in emergency services worldwide, such as assessing which patients need to be reassessed more frequently.
All systematic reviews scored poorly on the AMSTAR 2 critical appraisal tool for systematic reviews. Most of the original studies included in the reviews were case series and case reports, impacting the quality of evidence. Such evidence has major implications for clinical practice and the use of these reviews in evidence-based practice and policy. Clinicians, patients, and policymakers can only have the highest confidence in systematic review findings if high-quality systematic review methodologies are employed. The urgent need for information during a pandemic does not justify poor quality reporting.
We acknowledge that there are numerous challenges associated with analyzing COVID-19 data during a pandemic [ 47 ]. High-quality evidence syntheses are needed for decision-making, but each type of evidence syntheses is associated with its inherent challenges.
The creation of classic systematic reviews requires considerable time and effort; with massive research output, they quickly become outdated, and preparing updated versions also requires considerable time. A recent study showed that updates of non-Cochrane systematic reviews are published a median of 5 years after the publication of the previous version [ 48 ].
Authors may register a review and then abandon it [ 49 ], but the existence of a public record that is not updated may lead other authors to believe that the review is still ongoing. A quarter of Cochrane review protocols remains unpublished as completed systematic reviews 8 years after protocol publication [ 50 ].
Rapid reviews can be used to summarize the evidence, but they involve methodological sacrifices and simplifications to produce information promptly, with inconsistent methodological approaches [ 51 ]. However, rapid reviews are justified in times of public health emergencies, and even Cochrane has resorted to publishing rapid reviews in response to the COVID-19 crisis [ 52 ]. Rapid reviews were eligible for inclusion in this overview, but only one of the 18 reviews included in this study was labeled as a rapid review.
Ideally, COVID-19 evidence would be continually summarized in a series of high-quality living systematic reviews, types of evidence synthesis defined as “ a systematic review which is continually updated, incorporating relevant new evidence as it becomes available ” [ 53 ]. However, conducting living systematic reviews requires considerable resources, calling into question the sustainability of such evidence synthesis over long periods [ 54 ].
Research reports about COVID-19 will contribute to research waste if they are poorly designed, poorly reported, or simply not necessary. In principle, systematic reviews should help reduce research waste as they usually provide recommendations for further research that is needed or may advise that sufficient evidence exists on a particular topic [ 55 ]. However, systematic reviews can also contribute to growing research waste when they are not needed, or poorly conducted and reported. Our present study clearly shows that most of the systematic reviews that were published early on in the COVID-19 pandemic could be categorized as research waste, as our confidence in their results is critically low.
Our study has some limitations. One is that for AMSTAR 2 assessment we relied on information available in publications; we did not attempt to contact study authors for clarifications or additional data. In three reviews, the methodological quality appraisal was challenging because they were published as letters, or labeled as rapid communications. As a result, various details about their review process were not included, leading to AMSTAR 2 questions being answered as “not reported”, resulting in low confidence scores. Full manuscripts might have provided additional information that could have led to higher confidence in the results. In other words, low scores could reflect incomplete reporting, not necessarily low-quality review methods. To make their review available more rapidly and more concisely, the authors may have omitted methodological details. A general issue during a crisis is that speed and completeness must be balanced. However, maintaining high standards requires proper resourcing and commitment to ensure that the users of systematic reviews can have high confidence in the results.
Furthermore, we used adjusted AMSTAR 2 scoring, as the tool was designed for critical appraisal of reviews of interventions. Some reviews may have received lower scores than actually warranted in spite of these adjustments.
Another limitation of our study may be the inclusion of multiple overlapping reviews, as some included reviews included the same primary studies. According to the Cochrane Handbook, including overlapping reviews may be appropriate when the review’s aim is “ to present and describe the current body of systematic review evidence on a topic ” [ 12 ], which was our aim. To avoid bias with summarizing evidence from overlapping reviews, we presented the forest plots without summary estimates. The forest plots serve to inform readers about the effect sizes for outcomes that were reported in each review.
Several authors from this study have contributed to one of the reviews identified [ 25 ]. To reduce the risk of any bias, two authors who did not co-author the review in question initially assessed its quality and limitations.
Finally, we note that the systematic reviews included in our overview may have had issues that our analysis did not identify because we did not analyze their primary studies to verify the accuracy of the data and information they presented. We give two examples to substantiate this possibility. Lovato et al. wrote a commentary on the review of Sun et al. [ 41 ], in which they criticized the authors’ conclusion that sore throat is rare in COVID-19 patients [ 56 ]. Lovato et al. highlighted that multiple studies included in Sun et al. did not accurately describe participants’ clinical presentations, warning that only three studies clearly reported data on sore throat [ 56 ].
In another example, Leung [ 57 ] warned about the review of Li, L.Q. et al. [ 29 ]: “ it is possible that this statistic was computed using overlapped samples, therefore some patients were double counted ”. Li et al. responded to Leung that it is uncertain whether the data overlapped, as they used data from published articles and did not have access to the original data; they also reported that they requested original data and that they plan to re-do their analyses once they receive them; they also urged readers to treat the data with caution [ 58 ]. This points to the evolving nature of evidence during a crisis.
Our study’s strength is that this overview adds to the current knowledge by providing a comprehensive summary of all the evidence synthesis about COVID-19 available early after the onset of the pandemic. This overview followed strict methodological criteria, including a comprehensive and sensitive search strategy and a standard tool for methodological appraisal of systematic reviews.
In conclusion, in this overview of systematic reviews, we analyzed evidence from the first 18 systematic reviews that were published after the emergence of COVID-19. However, confidence in the results of all the reviews was “critically low”. Thus, systematic reviews that were published early on in the pandemic could be categorized as research waste. Even during public health emergencies, studies and systematic reviews should adhere to established methodological standards to provide patients, clinicians, and decision-makers trustworthy evidence.
Availability of data and materials
All data collected and analyzed within this study are available from the corresponding author on reasonable request.
World Health Organization. Timeline - COVID-19: Available at: https://www.who.int/news/item/29-06-2020-covidtimeline . Accessed 1 June 2021.
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: https://coronavirus.jhu.edu/map.html . Accessed 1 June 2021.
Anzai A, Kobayashi T, Linton NM, Kinoshita R, Hayashi K, Suzuki A, et al. Assessing the Impact of Reduced Travel on Exportation Dynamics of Novel Coronavirus Infection (COVID-19). J Clin Med. 2020;9(2):601.
Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020;368(6489):395–400. https://doi.org/10.1126/science.aba9757 .
Article CAS PubMed PubMed Central Google Scholar
Fidahic M, Nujic D, Runjic R, Civljak M, Markotic F, Lovric Makaric Z, et al. Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19. BMC Med Res Methodol. 2020;20(1):161. https://doi.org/10.1186/s12874-020-01047-2 .
EPPI Centre . COVID-19: a living systematic map of the evidence. Available at: http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingsystematicmapoftheevidence/tabid/3765/Default.aspx . Accessed 1 June 2021.
NCBI SARS-CoV-2 Resources. Available at: https://www.ncbi.nlm.nih.gov/sars-cov-2/ . Accessed 1 June 2021.
Gustot T. Quality and reproducibility during the COVID-19 pandemic. JHEP Rep. 2020;2(4):100141. https://doi.org/10.1016/j.jhepr.2020.100141 .
Article PubMed PubMed Central Google Scholar
Kodvanj, I., et al., Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. Preprint article. bioRxiv 2020.11.23.394577; doi: https://doi.org/10.1101/2020.11.23.394577 .
Dobler CC. Poor quality research and clinical practice during COVID-19. Breathe (Sheff). 2020;16(2):200112. https://doi.org/10.1183/20734735.0112-2020 .
Article Google Scholar
Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010;7(9):e1000326. https://doi.org/10.1371/journal.pmed.1000326 .
Lunny C, Brennan SE, McDonald S, McKenzie JE. Toward a comprehensive evidence map of overview of systematic review methods: paper 1-purpose, eligibility, search and data extraction. Syst Rev. 2017;6(1):231. https://doi.org/10.1186/s13643-017-0617-1 .
Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L. Chapter V: Overviews of Reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane. 2020. Available from www.training.cochrane.org/handbook .
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Cochrane. 2020; Available from www.training.cochrane.org/handbook .
Pollock M, Fernandes RM, Newton AS, Scott SD, Hartling L. The impact of different inclusion decisions on the comprehensiveness and complexity of overviews of reviews of healthcare interventions. Syst Rev. 2019;8(1):18. https://doi.org/10.1186/s13643-018-0914-3 .
Pollock M, Fernandes RM, Newton AS, Scott SD, Hartling L. A decision tool to help researchers make decisions about including systematic reviews in overviews of reviews of healthcare interventions. Syst Rev. 2019;8(1):29. https://doi.org/10.1186/s13643-018-0768-8 .
Hunt H, Pollock A, Campbell P, Estcourt L, Brunton G. An introduction to overviews of reviews: planning a relevant research question and objective for an overview. Syst Rev. 2018;7(1):39. https://doi.org/10.1186/s13643-018-0695-8 .
Pollock M, Fernandes RM, Pieper D, Tricco AC, Gates M, Gates A, et al. Preferred reporting items for overviews of reviews (PRIOR): a protocol for development of a reporting guideline for overviews of reviews of healthcare interventions. Syst Rev. 2019;8(1):335. https://doi.org/10.1186/s13643-019-1252-9 .
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3(3):e123–30.
Krnic Martinic M, Pieper D, Glatt A, Puljak L. Definition of a systematic review used in overviews of systematic reviews, meta-epidemiological studies and textbooks. BMC Med Res Methodol. 2019;19(1):203. https://doi.org/10.1186/s12874-019-0855-0 .
Puljak L. If there is only one author or only one database was searched, a study should not be called a systematic review. J Clin Epidemiol. 2017;91:4–5. https://doi.org/10.1016/j.jclinepi.2017.08.002 .
Article PubMed Google Scholar
Gates M, Gates A, Guitard S, Pollock M, Hartling L. Guidance for overviews of reviews continues to accumulate, but important challenges remain: a scoping review. Syst Rev. 2020;9(1):254. https://doi.org/10.1186/s13643-020-01509-0 .
Covidence - systematic review software. Available at: https://www.covidence.org/ . Accessed 1 June 2021.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
Borges do Nascimento IJ, et al. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. J Clin Med. 2020;9(4):941.
Article PubMed Central Google Scholar
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. https://doi.org/10.1186/s40249-020-00646-x .
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–83. https://doi.org/10.1016/j.jcrc.2020.03.005 .
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–8. https://doi.org/10.1007/s00392-020-01626-9 .
Article CAS PubMed Google Scholar
Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–83. https://doi.org/10.1002/jmv.25757 .
Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390–1. https://doi.org/10.1016/j.pcad.2020.03.001 .
Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107–8. https://doi.org/10.1016/j.ejim.2020.03.014 .
Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190–1. https://doi.org/10.1016/j.cca.2020.03.004 .
Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–8. https://doi.org/10.1016/j.cca.2020.03.022 .
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088–95. https://doi.org/10.1111/apa.15270 .
Lupia T, Scabini S, Mornese Pinna S, di Perri G, de Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: a new challenge. J Glob Antimicrob Resist. 2020;21:22–7. https://doi.org/10.1016/j.jgar.2020.02.021 .
Marasinghe, K.M., A systematic review investigating the effectiveness of face mask use in limiting the spread of COVID-19 among medically not diagnosed individuals: shedding light on current recommendations provided to individuals not medically diagnosed with COVID-19. Research Square. Preprint article. doi : https://doi.org/10.21203/rs.3.rs-16701/v1 . 2020 .
Mullins E, Evans D, Viner RM, O’Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound Obstet Gynecol. 2020;55(5):586–92. https://doi.org/10.1002/uog.22014 .
Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JIP, et al. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020;9(3):623.
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. https://doi.org/10.1016/j.tmaid.2020.101623 .
Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020;215(1):87–93. https://doi.org/10.2214/AJR.20.23034 .
Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020;92(6):612–7. https://doi.org/10.1002/jmv.25735 .
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5. https://doi.org/10.1016/j.ijid.2020.03.017 .
Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Investig. 2020;50(3):e13209. https://doi.org/10.1111/eci.13209 .
Article CAS Google Scholar
Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: report of a case. Acta Neurol Taiwanica. 2006;15(1):26–8.
Google Scholar
Suzuki M, Saito K, Min WP, Vladau C, Toida K, Itoh H, et al. Identification of viruses in patients with postviral olfactory dysfunction. Laryngoscope. 2007;117(2):272–7. https://doi.org/10.1097/01.mlg.0000249922.37381.1e .
Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020;20(7):776–7. https://doi.org/10.1016/S1473-3099(20)30244-9 .
Wolkewitz M, Puljak L. Methodological challenges of analysing COVID-19 data during the pandemic. BMC Med Res Methodol. 2020;20(1):81. https://doi.org/10.1186/s12874-020-00972-6 .
Rombey T, Lochner V, Puljak L, Könsgen N, Mathes T, Pieper D. Epidemiology and reporting characteristics of non-Cochrane updates of systematic reviews: a cross-sectional study. Res Synth Methods. 2020;11(3):471–83. https://doi.org/10.1002/jrsm.1409 .
Runjic E, Rombey T, Pieper D, Puljak L. Half of systematic reviews about pain registered in PROSPERO were not published and the majority had inaccurate status. J Clin Epidemiol. 2019;116:114–21. https://doi.org/10.1016/j.jclinepi.2019.08.010 .
Runjic E, Behmen D, Pieper D, Mathes T, Tricco AC, Moher D, et al. Following Cochrane review protocols to completion 10 years later: a retrospective cohort study and author survey. J Clin Epidemiol. 2019;111:41–8. https://doi.org/10.1016/j.jclinepi.2019.03.006 .
Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of rapid review methods. BMC Med. 2015;13(1):224. https://doi.org/10.1186/s12916-015-0465-6 .
COVID-19 Rapid Reviews: Cochrane’s response so far. Available at: https://training.cochrane.org/resource/covid-19-rapid-reviews-cochrane-response-so-far . Accessed 1 June 2021.
Cochrane. Living systematic reviews. Available at: https://community.cochrane.org/review-production/production-resources/living-systematic-reviews . Accessed 1 June 2021.
Millard T, Synnot A, Elliott J, Green S, McDonald S, Turner T. Feasibility and acceptability of living systematic reviews: results from a mixed-methods evaluation. Syst Rev. 2019;8(1):325. https://doi.org/10.1186/s13643-019-1248-5 .
Babic A, Poklepovic Pericic T, Pieper D, Puljak L. How to decide whether a systematic review is stable and not in need of updating: analysis of Cochrane reviews. Res Synth Methods. 2020;11(6):884–90. https://doi.org/10.1002/jrsm.1451 .
Lovato A, Rossettini G, de Filippis C. Sore throat in COVID-19: comment on “clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis”. J Med Virol. 2020;92(7):714–5. https://doi.org/10.1002/jmv.25815 .
Leung C. Comment on Li et al: COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(9):1431–2. https://doi.org/10.1002/jmv.25912 .
Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. Response to Char’s comment: comment on Li et al: COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(9):1433. https://doi.org/10.1002/jmv.25924 .
Download references
Acknowledgments
We thank Catherine Henderson DPhil from Swanscoe Communications for pro bono medical writing and editing support. We acknowledge support from the Covidence Team, specifically Anneliese Arno. We thank the whole International Network of Coronavirus Disease 2019 (InterNetCOVID-19) for their commitment and involvement. Members of the InterNetCOVID-19 are listed in Additional file 6 . We thank Pavel Cerny and Roger Crosthwaite for guiding the team supervisor (IJBN) on human resources management.
This research received no external funding.
Author information
Authors and affiliations.
University Hospital and School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Israel Júnior Borges do Nascimento & Milena Soriano Marcolino
Medical College of Wisconsin, Milwaukee, WI, USA
Israel Júnior Borges do Nascimento
Helene Fuld Health Trust National Institute for Evidence-based Practice in Nursing and Healthcare, College of Nursing, The Ohio State University, Columbus, OH, USA
Dónal P. O’Mathúna
School of Nursing, Psychotherapy and Community Health, Dublin City University, Dublin, Ireland
Department of Anesthesiology, Intensive Care and Pain Medicine, University of Münster, Münster, Germany
Thilo Caspar von Groote
Department of Sport and Health Science, Technische Universität München, Munich, Germany
Hebatullah Mohamed Abdulazeem
School of Health Sciences, Faculty of Health and Medicine, The University of Newcastle, Callaghan, Australia
Ishanka Weerasekara
Department of Physiotherapy, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka
Cochrane Croatia, University of Split, School of Medicine, Split, Croatia
Ana Marusic, Irena Zakarija-Grkovic & Tina Poklepovic Pericic
Center for Evidence-Based Medicine and Health Care, Catholic University of Croatia, Ilica 242, 10000, Zagreb, Croatia
Livia Puljak
Cochrane Brazil, Evidence-Based Health Program, Universidade Federal de São Paulo, São Paulo, Brazil
Vinicius Tassoni Civile & Alvaro Nagib Atallah
Yorkville University, Fredericton, New Brunswick, Canada
Santino Filoso
Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, Ontario, Canada
Nicola Luigi Bragazzi
You can also search for this author in PubMed Google Scholar
Contributions
IJBN conceived the research idea and worked as a project coordinator. DPOM, TCVG, HMA, IW, AM, LP, VTC, IZG, TPP, ANA, SF, NLB and MSM were involved in data curation, formal analysis, investigation, methodology, and initial draft writing. All authors revised the manuscript critically for the content. The author(s) read and approved the final manuscript.
Corresponding author
Correspondence to Livia Puljak .
Ethics declarations
Ethics approval and consent to participate.
Not required as data was based on published studies.
Consent for publication
Not applicable.
Competing interests
The authors declare no conflict of interest.
Additional information
Publisher’s note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1: appendix 1..
Search strategies used in the study.
Additional file 2: Appendix 2.
Adjusted scoring of AMSTAR 2 used in this study for systematic reviews of studies that did not analyze interventions.
Additional file 3: Appendix 3.
List of excluded studies, with reasons.
Additional file 4: Appendix 4.
Table of overlapping studies, containing the list of primary studies included, their visual overlap in individual systematic reviews, and the number in how many reviews each primary study was included.
Additional file 5: Appendix 5.
A detailed explanation of AMSTAR scoring for each item in each review.
Additional file 6: Appendix 6.
List of members and affiliates of International Network of Coronavirus Disease 2019 (InterNetCOVID-19).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reprints and permissions
About this article
Cite this article.
Borges do Nascimento, I.J., O’Mathúna, D.P., von Groote, T.C. et al. Coronavirus disease (COVID-19) pandemic: an overview of systematic reviews. BMC Infect Dis 21 , 525 (2021). https://doi.org/10.1186/s12879-021-06214-4
Download citation
Received : 12 April 2020
Accepted : 19 May 2021
Published : 04 June 2021
DOI : https://doi.org/10.1186/s12879-021-06214-4
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
- Coronavirus
- Evidence-based medicine
- Infectious diseases
BMC Infectious Diseases
ISSN: 1471-2334
- General enquiries: [email protected]
An official website of the United States government
Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
- Publications
- Account settings
- Advanced Search
- Journal List
A Review of Coronavirus Disease-2019 (COVID-19)
Tanu singhal.
- Author information
- Article notes
- Copyright and License information
Corresponding author.
Received 2020 Feb 23; Accepted 2020 Feb 25; Issue date 2020.
This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of coronavirus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The case fatality rate is estimated to range from 2 to 3%. Diagnosis is by demonstration of the virus in respiratory secretions by special molecular tests. Common laboratory findings include normal/ low white cell counts with elevated C-reactive protein (CRP). The computerized tomographic chest scan is usually abnormal even in those with no symptoms or mild disease. Treatment is essentially supportive; role of antiviral agents is yet to be established. Prevention entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality. The global impact of this new epidemic is yet uncertain.
Keywords: 2019-nCOV, SARS-CoV-2, COVID-19, Pneumonia, Review
Introduction
The 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) as it is now called, is rapidly spreading from its origin in Wuhan City of Hubei Province of China to the rest of the world [ 1 ]. Till 05/03/2020 around 96,000 cases of coronavirus disease 2019 (COVID-19) and 3300 deaths have been reported [ 2 ]. India has reported 29 cases till date. Fortunately so far, children have been infrequently affected with no deaths. But the future course of this virus is unknown. This article gives a bird’s eye view about this new virus. Since knowledge about this virus is rapidly evolving, readers are urged to update themselves regularly.
Coronaviruses are enveloped positive sense RNA viruses ranging from 60 nm to 140 nm in diameter with spike like projections on its surface giving it a crown like appearance under the electron microscope; hence the name coronavirus [ 3 ]. Four corona viruses namely HKU1, NL63, 229E and OC43 have been in circulation in humans, and generally cause mild respiratory disease.
There have been two events in the past two decades wherein crossover of animal betacorona viruses to humans has resulted in severe disease. The first such instance was in 2002–2003 when a new coronavirus of the β genera and with origin in bats crossed over to humans via the intermediary host of palm civet cats in the Guangdong province of China. This virus, designated as severe acute respiratory syndrome coronavirus affected 8422 people mostly in China and Hong Kong and caused 916 deaths (mortality rate 11%) before being contained [ 4 ]. Almost a decade later in 2012, the Middle East respiratory syndrome coronavirus (MERS-CoV), also of bat origin, emerged in Saudi Arabia with dromedary camels as the intermediate host and affected 2494 people and caused 858 deaths (fatality rate 34%) [ 5 ].
Origin and Spread of COVID-19 [ 1 , 2 , 6 ]
In December 2019, adults in Wuhan, capital city of Hubei province and a major transportation hub of China started presenting to local hospitals with severe pneumonia of unknown cause. Many of the initial cases had a common exposure to the Huanan wholesale seafood market that also traded live animals. The surveillance system (put into place after the SARS outbreak) was activated and respiratory samples of patients were sent to reference labs for etiologic investigations. On December 31st 2019, China notified the outbreak to the World Health Organization and on 1st January the Huanan sea food market was closed. On 7th January the virus was identified as a coronavirus that had >95% homology with the bat coronavirus and > 70% similarity with the SARS- CoV. Environmental samples from the Huanan sea food market also tested positive, signifying that the virus originated from there [ 7 ]. The number of cases started increasing exponentially, some of which did not have exposure to the live animal market, suggestive of the fact that human-to-human transmission was occurring [ 8 ]. The first fatal case was reported on 11th Jan 2020. The massive migration of Chinese during the Chinese New Year fuelled the epidemic. Cases in other provinces of China, other countries (Thailand, Japan and South Korea in quick succession) were reported in people who were returning from Wuhan. Transmission to healthcare workers caring for patients was described on 20th Jan, 2020. By 23rd January, the 11 million population of Wuhan was placed under lock down with restrictions of entry and exit from the region. Soon this lock down was extended to other cities of Hubei province. Cases of COVID-19 in countries outside China were reported in those with no history of travel to China suggesting that local human-to-human transmission was occurring in these countries [ 9 ]. Airports in different countries including India put in screening mechanisms to detect symptomatic people returning from China and placed them in isolation and testing them for COVID-19. Soon it was apparent that the infection could be transmitted from asymptomatic people and also before onset of symptoms. Therefore, countries including India who evacuated their citizens from Wuhan through special flights or had travellers returning from China, placed all people symptomatic or otherwise in isolation for 14 d and tested them for the virus.
Cases continued to increase exponentially and modelling studies reported an epidemic doubling time of 1.8 d [ 10 ]. In fact on the 12th of February, China changed its definition of confirmed cases to include patients with negative/ pending molecular tests but with clinical, radiologic and epidemiologic features of COVID-19 leading to an increase in cases by 15,000 in a single day [ 6 ]. As of 05/03/2020 96,000 cases worldwide (80,000 in China) and 87 other countries and 1 international conveyance (696, in the cruise ship Diamond Princess parked off the coast of Japan) have been reported [ 2 ]. It is important to note that while the number of new cases has reduced in China lately, they have increased exponentially in other countries including South Korea, Italy and Iran. Of those infected, 20% are in critical condition, 25% have recovered, and 3310 (3013 in China and 297 in other countries) have died [ 2 ]. India, which had reported only 3 cases till 2/3/2020, has also seen a sudden spurt in cases. By 5/3/2020, 29 cases had been reported; mostly in Delhi, Jaipur and Agra in Italian tourists and their contacts. One case was reported in an Indian who traveled back from Vienna and exposed a large number of school children in a birthday party at a city hotel. Many of the contacts of these cases have been quarantined.
These numbers are possibly an underestimate of the infected and dead due to limitations of surveillance and testing. Though the SARS-CoV-2 originated from bats, the intermediary animal through which it crossed over to humans is uncertain. Pangolins and snakes are the current suspects.
Epidemiology and Pathogenesis [ 10 , 11 ]
All ages are susceptible. Infection is transmitted through large droplets generated during coughing and sneezing by symptomatic patients but can also occur from asymptomatic people and before onset of symptoms [ 9 ]. Studies have shown higher viral loads in the nasal cavity as compared to the throat with no difference in viral burden between symptomatic and asymptomatic people [ 12 ]. Patients can be infectious for as long as the symptoms last and even on clinical recovery. Some people may act as super spreaders; a UK citizen who attended a conference in Singapore infected 11 other people while staying in a resort in the French Alps and upon return to the UK [ 6 ]. These infected droplets can spread 1–2 m and deposit on surfaces. The virus can remain viable on surfaces for days in favourable atmospheric conditions but are destroyed in less than a minute by common disinfectants like sodium hypochlorite, hydrogen peroxide etc. [ 13 ]. Infection is acquired either by inhalation of these droplets or touching surfaces contaminated by them and then touching the nose, mouth and eyes. The virus is also present in the stool and contamination of the water supply and subsequent transmission via aerosolization/feco oral route is also hypothesized [ 6 ]. As per current information, transplacental transmission from pregnant women to their fetus has not been described [ 14 ]. However, neonatal disease due to post natal transmission is described [ 14 ]. The incubation period varies from 2 to 14 d [median 5 d]. Studies have identified angiotensin receptor 2 (ACE 2 ) as the receptor through which the virus enters the respiratory mucosa [ 11 ].
The basic case reproduction rate (BCR) is estimated to range from 2 to 6.47 in various modelling studies [ 11 ]. In comparison, the BCR of SARS was 2 and 1.3 for pandemic flu H1N1 2009 [ 2 ].
Clinical Features [ 8 , 15 – 18 ]
The clinical features of COVID-19 are varied, ranging from asymptomatic state to acute respiratory distress syndrome and multi organ dysfunction. The common clinical features include fever (not in all), cough, sore throat, headache, fatigue, headache, myalgia and breathlessness. Conjunctivitis has also been described. Thus, they are indistinguishable from other respiratory infections. In a subset of patients, by the end of the first week the disease can progress to pneumonia, respiratory failure and death. This progression is associated with extreme rise in inflammatory cytokines including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNFα [ 15 ]. The median time from onset of symptoms to dyspnea was 5 d, hospitalization 7 d and acute respiratory distress syndrome (ARDS) 8 d. The need for intensive care admission was in 25–30% of affected patients in published series. Complications witnessed included acute lung injury, ARDS, shock and acute kidney injury. Recovery started in the 2nd or 3rd wk. The median duration of hospital stay in those who recovered was 10 d. Adverse outcomes and death are more common in the elderly and those with underlying co-morbidities (50–75% of fatal cases). Fatality rate in hospitalized adult patients ranged from 4 to 11%. The overall case fatality rate is estimated to range between 2 and 3% [ 2 ].
Interestingly, disease in patients outside Hubei province has been reported to be milder than those from Wuhan [ 17 ]. Similarly, the severity and case fatality rate in patients outside China has been reported to be milder [ 6 ]. This may either be due to selection bias wherein the cases reporting from Wuhan included only the severe cases or due to predisposition of the Asian population to the virus due to higher expression of ACE 2 receptors on the respiratory mucosa [ 11 ].
Disease in neonates, infants and children has been also reported to be significantly milder than their adult counterparts. In a series of 34 children admitted to a hospital in Shenzhen, China between January 19th and February 7th, there were 14 males and 20 females. The median age was 8 y 11 mo and in 28 children the infection was linked to a family member and 26 children had history of travel/residence to Hubei province in China. All the patients were either asymptomatic (9%) or had mild disease. No severe or critical cases were seen. The most common symptoms were fever (50%) and cough (38%). All patients recovered with symptomatic therapy and there were no deaths. One case of severe pneumonia and multiorgan dysfunction in a child has also been reported [ 19 ]. Similarly the neonatal cases that have been reported have been mild [ 20 ].
Diagnosis [ 21 ]
A suspect case is defined as one with fever, sore throat and cough who has history of travel to China or other areas of persistent local transmission or contact with patients with similar travel history or those with confirmed COVID-19 infection. However cases may be asymptomatic or even without fever. A confirmed case is a suspect case with a positive molecular test.
Specific diagnosis is by specific molecular tests on respiratory samples (throat swab/ nasopharyngeal swab/ sputum/ endotracheal aspirates and bronchoalveolar lavage). Virus may also be detected in the stool and in severe cases, the blood. It must be remembered that the multiplex PCR panels currently available do not include the COVID-19. Commercial tests are also not available at present. In a suspect case in India, the appropriate sample has to be sent to designated reference labs in India or the National Institute of Virology in Pune. As the epidemic progresses, commercial tests will become available.
Other laboratory investigations are usually non specific. The white cell count is usually normal or low. There may be lymphopenia; a lymphocyte count <1000 has been associated with severe disease. The platelet count is usually normal or mildly low. The CRP and ESR are generally elevated but procalcitonin levels are usually normal. A high procalcitonin level may indicate a bacterial co-infection. The ALT/AST, prothrombin time, creatinine, D-dimer, CPK and LDH may be elevated and high levels are associated with severe disease.
The chest X-ray (CXR) usually shows bilateral infiltrates but may be normal in early disease. The CT is more sensitive and specific. CT imaging generally shows infiltrates, ground glass opacities and sub segmental consolidation. It is also abnormal in asymptomatic patients/ patients with no clinical evidence of lower respiratory tract involvement. In fact, abnormal CT scans have been used to diagnose COVID-19 in suspect cases with negative molecular diagnosis; many of these patients had positive molecular tests on repeat testing [ 22 ].
Differential Diagnosis [ 21 ]
The differential diagnosis includes all types of respiratory viral infections [influenza, parainfluenza, respiratory syncytial virus (RSV), adenovirus, human metapneumovirus, non COVID-19 coronavirus], atypical organisms (mycoplasma, chlamydia) and bacterial infections. It is not possible to differentiate COVID-19 from these infections clinically or through routine lab tests. Therefore travel history becomes important. However, as the epidemic spreads, the travel history will become irrelevant.
Treatment [ 21 , 23 ]
Treatment is essentially supportive and symptomatic.
The first step is to ensure adequate isolation (discussed later) to prevent transmission to other contacts, patients and healthcare workers. Mild illness should be managed at home with counseling about danger signs. The usual principles are maintaining hydration and nutrition and controlling fever and cough. Routine use of antibiotics and antivirals such as oseltamivir should be avoided in confirmed cases. In hypoxic patients, provision of oxygen through nasal prongs, face mask, high flow nasal cannula (HFNC) or non-invasive ventilation is indicated. Mechanical ventilation and even extra corporeal membrane oxygen support may be needed. Renal replacement therapy may be needed in some. Antibiotics and antifungals are required if co-infections are suspected or proven. The role of corticosteroids is unproven; while current international consensus and WHO advocate against their use, Chinese guidelines do recommend short term therapy with low-to-moderate dose corticosteroids in COVID-19 ARDS [ 24 , 25 ]. Detailed guidelines for critical care management for COVID-19 have been published by the WHO [ 26 ]. There is, as of now, no approved treatment for COVID-19. Antiviral drugs such as ribavirin, lopinavir-ritonavir have been used based on the experience with SARS and MERS. In a historical control study in patients with SARS, patients treated with lopinavir-ritonavir with ribavirin had better outcomes as compared to those given ribavirin alone [ 15 ].
In the case series of 99 hospitalized patients with COVID-19 infection from Wuhan, oxygen was given to 76%, non-invasive ventilation in 13%, mechanical ventilation in 4%, extracorporeal membrane oxygenation (ECMO) in 3%, continuous renal replacement therapy (CRRT) in 9%, antibiotics in 71%, antifungals in 15%, glucocorticoids in 19% and intravenous immunoglobulin therapy in 27% [ 15 ]. Antiviral therapy consisting of oseltamivir, ganciclovir and lopinavir-ritonavir was given to 75% of the patients. The duration of non-invasive ventilation was 4–22 d [median 9 d] and mechanical ventilation for 3–20 d [median 17 d]. In the case series of children discussed earlier, all children recovered with basic treatment and did not need intensive care [ 17 ].
There is anecdotal experience with use of remdeswir, a broad spectrum anti RNA drug developed for Ebola in management of COVID-19 [ 27 ]. More evidence is needed before these drugs are recommended. Other drugs proposed for therapy are arbidol (an antiviral drug available in Russia and China), intravenous immunoglobulin, interferons, chloroquine and plasma of patients recovered from COVID-19 [ 21 , 28 , 29 ]. Additionally, recommendations about using traditional Chinese herbs find place in the Chinese guidelines [ 21 ].
Prevention [ 21 , 30 ]
Since at this time there are no approved treatments for this infection, prevention is crucial. Several properties of this virus make prevention difficult namely, non-specific features of the disease, the infectivity even before onset of symptoms in the incubation period, transmission from asymptomatic people, long incubation period, tropism for mucosal surfaces such as the conjunctiva, prolonged duration of the illness and transmission even after clinical recovery.
Isolation of confirmed or suspected cases with mild illness at home is recommended. The ventilation at home should be good with sunlight to allow for destruction of virus. Patients should be asked to wear a simple surgical mask and practice cough hygiene. Caregivers should be asked to wear a surgical mask when in the same room as patient and use hand hygiene every 15–20 min.
The greatest risk in COVID-19 is transmission to healthcare workers. In the SARS outbreak of 2002, 21% of those affected were healthcare workers [ 31 ]. Till date, almost 1500 healthcare workers in China have been infected with 6 deaths. The doctor who first warned about the virus has died too. It is important to protect healthcare workers to ensure continuity of care and to prevent transmission of infection to other patients. While COVID-19 transmits as a droplet pathogen and is placed in Category B of infectious agents (highly pathogenic H5N1 and SARS), by the China National Health Commission, infection control measures recommended are those for category A agents (cholera, plague). Patients should be placed in separate rooms or cohorted together. Negative pressure rooms are not generally needed. The rooms and surfaces and equipment should undergo regular decontamination preferably with sodium hypochlorite. Healthcare workers should be provided with fit tested N95 respirators and protective suits and goggles. Airborne transmission precautions should be taken during aerosol generating procedures such as intubation, suction and tracheostomies. All contacts including healthcare workers should be monitored for development of symptoms of COVID-19. Patients can be discharged from isolation once they are afebrile for atleast 3 d and have two consecutive negative molecular tests at 1 d sampling interval. This recommendation is different from pandemic flu where patients were asked to resume work/school once afebrile for 24 h or by day 7 of illness. Negative molecular tests were not a prerequisite for discharge.
At the community level, people should be asked to avoid crowded areas and postpone non-essential travel to places with ongoing transmission. They should be asked to practice cough hygiene by coughing in sleeve/ tissue rather than hands and practice hand hygiene frequently every 15–20 min. Patients with respiratory symptoms should be asked to use surgical masks. The use of mask by healthy people in public places has not shown to protect against respiratory viral infections and is currently not recommended by WHO. However, in China, the public has been asked to wear masks in public and especially in crowded places and large scale gatherings are prohibited (entertainment parks etc). China is also considering introducing legislation to prohibit selling and trading of wild animals [ 32 ].
The international response has been dramatic. Initially, there were massive travel restrictions to China and people returning from China/ evacuated from China are being evaluated for clinical symptoms, isolated and tested for COVID-19 for 2 wks even if asymptomatic. However, now with rapid world wide spread of the virus these travel restrictions have extended to other countries. Whether these efforts will lead to slowing of viral spread is not known.
A candidate vaccine is under development.
Practice Points from an Indian Perspective
At the time of writing this article, the risk of coronavirus in India is extremely low. But that may change in the next few weeks. Hence the following is recommended:
Healthcare providers should take travel history of all patients with respiratory symptoms, and any international travel in the past 2 wks as well as contact with sick people who have travelled internationally.
They should set up a system of triage of patients with respiratory illness in the outpatient department and give them a simple surgical mask to wear. They should use surgical masks themselves while examining such patients and practice hand hygiene frequently.
Suspected cases should be referred to government designated centres for isolation and testing (in Mumbai, at this time, it is Kasturba hospital). Commercial kits for testing are not yet available in India.
Patients admitted with severe pneumonia and acute respiratory distress syndrome should be evaluated for travel history and placed under contact and droplet isolation. Regular decontamination of surfaces should be done. They should be tested for etiology using multiplex PCR panels if logistics permit and if no pathogen is identified, refer the samples for testing for SARS-CoV-2.
All clinicians should keep themselves updated about recent developments including global spread of the disease.
Non-essential international travel should be avoided at this time.
People should stop spreading myths and false information about the disease and try to allay panic and anxiety of the public.
Conclusions
This new virus outbreak has challenged the economic, medical and public health infrastructure of China and to some extent, of other countries especially, its neighbours. Time alone will tell how the virus will impact our lives here in India. More so, future outbreaks of viruses and pathogens of zoonotic origin are likely to continue. Therefore, apart from curbing this outbreak, efforts should be made to devise comprehensive measures to prevent future outbreaks of zoonotic origin.
Compliance with Ethical Standards
Conflict of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1. Wang Chen, Horby Peter W, Hayden Frederick G, Gao George F. A novel coronavirus outbreak of global health concern. The Lancet. 2020;395(10223):470–473. doi: 10.1016/S0140-6736(20)30185-9. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 2. Coronavirus Outbreak. Available at: https://www.worldometers.info/coronavirus/ . Accessed 23 Feb 2020.
- 3. Richman DD, Whitley RJ, Hayden FG. Clinical Virology, 4th ed. Washington: ASM Press; 2016.
- 4. Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8:S9–14. doi: 10.1046/j.1440-1843.2003.00518.x. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 5. Middle East Respiratory Syndrome Coronavirus. Available at: https://www.who.int/emergencies/mers-cov/en/ . Accessed 16 Feb 2020.
- 6. World Health Organization. Situation reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ . Accessed 22 Feb 2020.
- 7. Xinhua. China’s CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan. Available at: https://www.xinhuanet.com/2020-01/27/c_1125504355.htm . Accessed 20 Feb 2020.
- 8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 9. Rothe Camilla, Schunk Mirjam, Sothmann Peter, Bretzel Gisela, Froeschl Guenter, Wallrauch Claudia, Zimmer Thorbjörn, Thiel Verena, Janke Christian, Guggemos Wolfgang, Seilmaier Michael, Drosten Christian, Vollmar Patrick, Zwirglmaier Katrin, Zange Sabine, Wölfel Roman, Hoelscher Michael. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. New England Journal of Medicine. 2020;382(10):970–971. doi: 10.1056/NEJMc2001468. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 10. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. 10.1056/NEJMoa2001316. [ DOI ] [ PMC free article ] [ PubMed ]
- 11. Cheng ZJ, Shan J. 2019 novel coronavirus: where we are and what we know. Infection. 2020:1–9. 10.1007/s15010-020-01401-y. [ DOI ] [ PMC free article ] [ PubMed ]
- 12. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020. 10.1056/NEJMc2001737. [ DOI ] [ PMC free article ] [ PubMed ]
- 13. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020 Feb 6. pii: S0195–6701(20)30046–3. [ DOI ] [ PMC free article ] [ PubMed ]
- 14. Chen Huijun, Guo Juanjuan, Wang Chen, Luo Fan, Yu Xuechen, Zhang Wei, Li Jiafu, Zhao Dongchi, Xu Dan, Gong Qing, Liao Jing, Yang Huixia, Hou Wei, Zhang Yuanzhen. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020;395(10226):809–815. doi: 10.1016/S0140-6736(20)30360-3. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 15. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 16. Wang Dawei, Hu Bo, Hu Chang, Zhu Fangfang, Liu Xing, Zhang Jing, Wang Binbin, Xiang Hui, Cheng Zhenshun, Xiong Yong, Zhao Yan, Li Yirong, Wang Xinghuan, Peng Zhiyong. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi: 10.1001/jama.2020.1585. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 17. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 18. Wang XF, Yuan J, Zheng YJ, et al. Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. [Article in Chinese]. Zhonghua Er Ke Za Zhi. 2020;58:E008. [ DOI ] [ PubMed ]
- 19. Chen F, Liu ZS, Zhang FR, et al. First case of severe childhood novel coronavirus pneumonia in China. Zhonghua Er Ke Za Zhi. 2020;58:E005. doi: 10.3760/cma.j.issn.0578-1310.2020.0005. [ DOI ] [ PubMed ] [ Google Scholar ]
- 20. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. First case of neonate infected with novel coronavirus pneumonia in China. Zhonghua Er Ke Za Zhi. 2020;58:E009. doi: 10.3760/cma.j.issn.0578-1310.2020.0009. [ DOI ] [ PubMed ] [ Google Scholar ]
- 21. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus [2019-nCoV] infected pneumonia [standard version] Mil Med Res. 2020;7:4. doi: 10.1186/s40779-020-0233-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 22. Huang Peikai, Liu Tianzhu, Huang Lesheng, Liu Hailong, Lei Ming, Xu Wangdong, Hu Xiaolu, Chen Jun, Liu Bo. Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. Radiology. 2020;295(1):22–23. doi: 10.1148/radiol.2020200330. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 23. Chen Z-M, Fu J-F, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020:1–7. 10.1007/s12519-020-00345-5. [ DOI ] [ PMC free article ] [ PubMed ]
- 24. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 25. Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E007. doi: 10.3760/cma.j.issn.1001-0939.2020.0007. [ DOI ] [ PubMed ] [ Google Scholar ]
- 26. WHO. Clinical management of severe acute respiratory infection when novel coronavirus [nCoV] infection is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-[ncov]-infection-is-suspected . Accessed 9 Feb 2020.
- 27. Holshue Michelle L., DeBolt Chas, Lindquist Scott, Lofy Kathy H., Wiesman John, Bruce Hollianne, Spitters Christopher, Ericson Keith, Wilkerson Sara, Tural Ahmet, Diaz George, Cohn Amanda, Fox LeAnne, Patel Anita, Gerber Susan I., Kim Lindsay, Tong Suxiang, Lu Xiaoyan, Lindstrom Steve, Pallansch Mark A., Weldon William C., Biggs Holly M., Uyeki Timothy M., Pillai Satish K. First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine. 2020;382(10):929–936. doi: 10.1056/NEJMoa2001191. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 28. Zhang Lei, Liu Yunhui. Potential interventions for novel coronavirus in China: A systematic review. Journal of Medical Virology. 2020;92(5):479–490. doi: 10.1002/jmv.25707. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 29. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. [Article in Chinese] Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E019. [ DOI ] [ PubMed ]
- 30. World Health Organization. Coronavirus disease [COVID-19] Technical Guidance: Infection Prevention and Control. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control . Accessed 20 Feb 2020.
- 31. Chang De, Xu Huiwen, Rebaza Andre, Sharma Lokesh, Dela Cruz Charles S. Protecting health-care workers from subclinical coronavirus infection. The Lancet Respiratory Medicine. 2020;8(3):e13. doi: 10.1016/S2213-2600(20)30066-7. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- 32. Li Jie, Li Jun (Justin), Xie Xiaoru, Cai Xiaomei, Huang Jian, Tian Xuemei, Zhu Hong. Game consumption and the 2019 novel coronavirus. The Lancet Infectious Diseases. 2020;20(3):275–276. doi: 10.1016/S1473-3099(20)30063-3. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
- View on publisher site
- PDF (201.7 KB)
- Collections
Similar articles
Cited by other articles, links to ncbi databases.
- Download .nbib .nbib
- Format: AMA APA MLA NLM
Add to Collections
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
- View all journals
- My Account Login
- Explore content
- About the journal
- Publish with us
- Sign up for alerts
- Review Article
- Open access
- Published: 08 November 2023
A comprehensive SARS-CoV-2 and COVID-19 review, Part 2: host extracellular to systemic effects of SARS-CoV-2 infection
- S. Anand Narayanan ORCID: orcid.org/0000-0002-9783-5711 1 , 2 na1 ,
- David A. Jamison Jr 1 na1 ,
- Joseph W. Guarnieri 1 , 3 ,
- Victoria Zaksas ORCID: orcid.org/0000-0001-7916-4902 1 , 4 , 5 ,
- Michael Topper 1 , 6 ,
- Andrew P. Koutnik 7 , 8 ,
- Jiwoon Park ORCID: orcid.org/0000-0003-0045-1429 9 , 10 ,
- Kevin B. Clark 1 , 11 , 12 , 13 , 14 , 15 ,
- Francisco J. Enguita 1 , 16 ,
- Ana Lúcia Leitão 17 ,
- Saswati Das ORCID: orcid.org/0000-0002-4548-0066 1 , 18 ,
- Pedro M. Moraes-Vieira ORCID: orcid.org/0000-0002-8263-786X 1 , 19 , 20 ,
- Diego Galeano 1 , 21 ,
- Christopher E. Mason ORCID: orcid.org/0000-0002-1850-1642 1 , 9 , 22 , 23 ,
- Nídia S. Trovão ORCID: orcid.org/0000-0002-2106-1166 1 , 24 ,
- Robert E. Schwartz 1 , 25 , 26 ,
- Jonathan C. Schisler 1 , 27 ,
- Jordana G. A. Coelho-dos-Reis 1 , 28 ,
- Eve Syrkin Wurtele 1 , 29 , 30 &
- Afshin Beheshti ORCID: orcid.org/0000-0003-4643-531X 1 , 31 , 32
European Journal of Human Genetics volume 32 , pages 10–20 ( 2024 ) Cite this article
23k Accesses
8 Citations
382 Altmetric
Metrics details
- Chronic inflammation
- Diagnostic markers
- Viral infection
COVID-19, the disease caused by SARS-CoV-2, has caused significant morbidity and mortality worldwide. The betacoronavirus continues to evolve with global health implications as we race to learn more to curb its transmission, evolution, and sequelae. The focus of this review, the second of a three-part series, is on the biological effects of the SARS-CoV-2 virus on post-acute disease in the context of tissue and organ adaptations and damage. We highlight the current knowledge and describe how virological, animal, and clinical studies have shed light on the mechanisms driving the varied clinical diagnoses and observations of COVID-19 patients. Moreover, we describe how investigations into SARS-CoV-2 effects have informed the understanding of viral pathogenesis and provide innovative pathways for future research on the mechanisms of viral diseases.
Similar content being viewed by others
A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection
Animal and translational models of SARS-CoV-2 infection and COVID-19
Coronavirus biology and replication: implications for SARS-CoV-2
Introduction.
As of January 13, 2023, over 671 million cases of the coronavirus disease 2019 (COVID-19) worldwide have been reported, and more than 6.71 million lives have been claimed globally. The COVID-19 pandemic is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The development and administration of vaccines and antiviral therapeutics against SARS-CoV-2 significantly reduced the local to global impact and burden of COVID-19. However, the global distribution of these resources has been unequal [ 1 ], ultimately prolonging viral transmission. Moreover, SARS-CoV-2 quickly evolved into variants with increased transmission rates more capable of immune escape [ 2 ]. Therefore, we must increase our understanding of this novel virus, its variants, and the resulting short- and long-term effects of COVID-19 on human health.
SARS-CoV-2 belongs to the genus Betacoronavirus, which includes viruses such as OC43, HKU1, SARS-CoV, and MERS-CoV [ 3 ]. SARS-CoV-2 is an enveloped positive-sense RNA virus, whose genome is packaged in a helical ribonucleocapsid complex. The outer surface of the virus is studded with Spike (S) proteins that facilitate the infection of host cells by binding to its cognate cellular surface receptor angiotensin-converting enzyme 2 (ACE2) through the S protein receptor binding domain (RBD) to allow for viral membrane fusion. Fusion leads to viral genome transfer into the host cell cytoplasm where viral replication can commence, leading to its various intracellular impacts. To read in more detail these processes, as well as structural elements of the SARS-CoV-2 virus, see our first review, ref. [ 3 ], focusing on intracellular SARS-CoV-2 viral effects [ 3 ].
In this second of a three-part comprehensive series of our series of SARS-CoV-2 reviews, we cover the extracellular and circulating signals and physiological effects of the viral disease, including the consequences and remodeling of organs, metabolism, humoral factors, and the immune system. In turn, the aim of this review series is to provide an overview of our current knowledge of SARS-CoV-2 and its biological effects from basic biology to clinical patient outcomes, highlighting also future areas of research given the ever-evolving nature of SARS-CoV-2,COVID-19, and its consequences for healthcare across the world.
Metabolic adaptations caused directly by viral infection of cells
We previously described [ 3 ] SARS-CoV-2 viral infection intracellular effects and host adaptations. These include major shifts in metabolic and biochemical pathways, including the oxidative phosphorylation and the tricarboxylic acid (TCA) cycle [ 3 ]. The immune system is also involved in these adaptations, with a study showing upregulation of Type I interferon (IFN) gene signaling pathways leading to changes with cellular responses to IFN and triggering changes with associated cytokine-mediated signaling pathways [ 4 ]. These stimuli lead to cellular adaptations including endoplasmic reticulum stress, upregulated unfolded protein response and downregulation of pathways including spliceosome-mediated RNA processing, mitochondrial electron transport chain inhibition, and impairment in the biogenesis and assembly of the electron transport chain complexes and oxidative phosphorylation [ 5 , 6 ]. Indeed, SARS-CoV-2 infection leads to decreased mitochondrial function, increased glycolysis, and shunting towards the pentose 5 phosphate pathway, resulting in changes in cellular metabolism and bioenergetics that lead to pathophysiological outcomes.
These various cellular biochemical adaptations also result in production of circulating metabolites in COVID-19 patients that lead to systemic effects, including tissue remodeling and function, shifts in whole-body metabolism and bioenergetics, changes with immune and endocrine state, etc., resulting in the symptoms and disease outcomes seen with COVID-19 patients. For example, the TCA cycle is the main cellular source of energy and critical for aerobic respiration; serum levels of the TCA metabolites (citrate, fumarate, malate, and aconitate) were significantly lower in the SARS-CoV-2-infected patients as compared with controls, with choline specifically observed to be decreased in patients with severe COVID-19 [ 7 ]. Serum metabolites that were increased in these patients included deoxy-thymidine, deoxyuridine, adenine, cystine, and homocysteine. These data provide context as to how specific biochemical and physiological pathways, e.g., the TCA cycle, shift as a result of COVID-19 infection and lead to pathogenesis. For example, elevated homocysteine is associated with endothelial damage [ 8 ]. These shifts in metabolites reflect a systemic shift during acute COVID-19 infection, and warrant study of subsequent specific organ adaptations (e.g., bone as a major source of citrate, which is released into the plasma during bone resorption, with soft tissues not generally providing a significant source of citrate into blood plasma).
Separate from metabolic pathways (e.g., oxidative phosphorylation, glycolysis, etc.) that produce energy from sugars are alternative pathways that utilize compounds such as lipids. Excess energy is stored in the form of lipids, with lipids also used as an immediate energy source or for later use. Lipids also serve as second messengers, activating protein and immune pathways. Indeed, it has been reported SARS-CoV-2 infection causes lipids levels to change and lipid metabolism to alter, with one study using untargeted metabolomic and lipidomic approaches observing specific circulating lipids associated with SARS-CoV-2 infection, including increases in triglycerides and free fatty acids (e.g., arachidonic acid and oleic acid). These lipids also correlated with disease severity [ 9 ]. A specific class of lipids are lipid mediators (LMs), which are bioactive lipids produced locally in response to extracellular stimuli and are involved in immune regulation. Studies have investigated their role in relation to COVID-19 severity as well. One report involving 19 healthy patients, 18 COVID-19 patients who did not need ICU admission (mild), and 20 patients that needed ICU admission (severe) showed an increase of free poly-unsaturated fatty acids (PUFAs) and diminished amounts of PUFA-containing plasmalogens in patients with COVID-19 that also correlated with disease severity [ 10 ]. Another study performing metabolomics and lipidomics measurements on patients (49 subjects, 33 were COVID-19–positive subjects and 16 COVID-19–negative subjects) showed alterations in fatty acid metabolism that were associated with SARS-CoV-2 infection. More specifically, short- and medium-chain acylcarnitines were significantly diminished in all patients with COVID-19, while all Non-Esterified Fatty Acids (except nonanoic acid) were increased in all COVID-19 patients [ 11 , 12 ].
In summary, SARS-CoV-2 infection affects whole-body metabolism in different ways, with emerging evidence supporting a correlation between these adaptations and COVID-19 disease severity. Moreover, the balance of biochemical components, whether the machinery (e.g., TCA proteins), fuel sources (e.g., lipids), or messenger molecules (e.g., metabolites) appear to shift towards a physiological catabolic state that may be further exacerbated by a patient’s underlying conditions and demographics [ 7 , 9 , 10 , 11 , 12 ]. Metabolic biofactors are also intrinsically tied with the recovery and response to viral infection, with immune-regulating lipids, pro-inflammatory lipids, and lipid mediators plausibly modulating the immune response during COVID-19, as one example. The immune system’s physiology is also reliant on its metabolic function, whether from a development, proliferation, activation, or memory perspective. Immunity is shaped and guided by humoral factors, which we address in the next section, as to the SARS-CoV-2 viral influence on these factors and the effects on the body.
Humoral adaptations and changes
Humoral factors are compounds that are transported by the circulatory system throughout the body, and include immune factors (e.g., cytokines, chemokines, antibodies, complement proteins, clotting factors, etc.), hormones, RNAs, lipids, metabolites, etc. These play a role in steady-state physiology as well as pathophysiological adaptations, with changes in humoral factors occurring from SARS-CoV-2 infection. One example is bradykinin, a peptide that is involved with physiological effects, including dilation of arterioles through release of prostacyclin, nitric oxide, and EDHF, constriction of veins by prostaglandin F2, as well as various biochemical effects including upregulation of intracellular Ca2+, regulation of cAMP/cGMP, arachidonic acid release, promotion of VEGF expression and angiogenesis, and activation of TGF-B, JAK/STAT pathways [ 13 ]. Additionally, bradykinin is degraded by angiotensin-converting enzyme (ACE) and enhanced by angiotensin produced by ACE2. Bradykinin, angiotensin, ACE, and ACE2, are all part of the renin-angiotensin system (RAS), which serves a role within the endocrine system in regulation of renal, cardiac, and vascular physiology, and in turn, systemic physiology [ 14 ]. Moreover, SARS-CoV-2 enters the cell through receptors such as ACE2 and NRP-1, in a process requiring the transmembrane protease 2 (TMPRSS2) protein [ 3 , 15 ]; thus, SARS-CoV-2 directly interacts with the RAS system and influences its activity. Indeed, gene analysis of bronchoalveolar lavage fluid from COVID-19 patients showed a critical imbalance of RAS-related factors, including decreased expression of ACE, while increases in ACE2, renin, angiotensin, and bradykinin, which were suggestive of elevated bradykinin levels systemically that lead to the cardiovascular symptoms seen with patients [ 16 ]. Another study of the bradykinin cascade of COVID-19 patients correlated changes in this pathway with disease severity, showing accumulated bradykinin levels were related with patient disease severity, as well as with levels of inflammation, coagulation, and lymphopenia [ 17 ].
In addition to the RAS axis, the endocrine system is also vulnerable to SARS-CoV-2 infection [ 14 , 15 ]. For example, the ACE2 receptor is expressed in endocrine glands, including the hypothalamus, pituitary gland, adrenals, pancreas, thyroid glands, ovaries, and testes [ 15 ]. Studies have shown reduced thyroid (e.g., subacute thyroiditis, thyrotoxicosis), adrenal (e.g., hypocortisolism, hyponatremia), hypothalamic-pituitary-thyroid (e.g., HPA dysfunction, hypocortisolism, hypothyroidism), and pancreatic islet function (e.g., hyperglycemia, pancreatic injury based from elevated amylase and lipase), as well as damage to the testes and changes with menstrual cycle being described in COVID-19 patients [ 14 , 15 ]. SARS-CoV-2 infection has also been suggested to affect glycemic control, with an international registry having been organized to investigate the interaction between diabetes and COVID-19 [ 14 ]. Moreover, clinical studies show more severe outcomes in patients with diabetes, obesity, and hypertension; however, there is a lack of data in humans on ACE2 expression in pathological conditions with endocrine tissues, an area which needs future investigation [ 15 ]. Various mouse studies have enabled us to investigate organ-specific adaptations, including examining the effects of ACE2 deletion in endocrine organs and observing the beneficial effects of ACE2 gene therapy [ 15 ]. The details of these studies are outside the scope of this review, but are elaborated in ref. [ 14 , 15 ]. As with bradykinin, the remodeling of endocrine factors results in changes with the factors that endocrine organs produce and secrete, though this is an area warrants more investigation. Indeed, these include the non-coding transcriptome, genes which are not involved with protein synthesis, but are transcribed and often secreted into the circulation, in turn providing information on the genetic state of their originating cells, but also controlling and regulating biological adaptations due to the ability of the non-coding RNAs to interact with other macromolecules, including DNA, RNA, and proteins. We elaborate on the changes with the non-coding RNA transcriptome seen in COVID-19 patients in the next section.
Exosomes influence on SARS-CoV-2 infection
Exosomes are extracellular vesicles generated by all cells that carry cellular components, including nucleic acids, proteins, lipids, and metabolites. They are carried and transported in blood and lymph, and serve near- and long-distance intercellular communication and biological effects. They also serve as a biomarker based on their contents, which may be altered in different conditions and physiological states. It is known that during viral infection, extracellular vesicles become vectors of viral material. More recent reports have also highlighted this occurs with SARS-CoV-2 infection [ 18 ].
One study investigated and compared exosomes from mild or severe COVID-19 patients. The exosomes from both groups contained SARS-CoV-2 spike-derived peptides and immunomodulatory molecules, though only those from mild patients could stimulate an antigen-specific CD4 T-cell response [ 19 ]. This study also observed that the proteome of exosomes of mild patients correlated with a normally functioning immune system, while that of severe patients was associated with increased and chronic inflammation.
As mentioned above, exosomes may affect distant cells, and one study explored this connection in the context of COVID-19 by evaluating exosome effects on endothelial cells from exosomes derived from plasma [ 19 ]. Exosomes affected the endothelial cells by inducing inflammation-related pathways (e.g., NRLP3, caspase-1, and interleukin-1-beta) through mRNA expression, compared with plasma from mild disease or healthy donors. The study showed that these adaptations were tied with exosomes containing tenascin-C and fibrinogen-beta, which triggered the inflammatory pathways by inducing NF-kB mediated pathways. While this study focused on endothelial cell responses, it was noted that these effects may promote inflammation in other cell types systemically.
Exosomes can also be involved with the inflammatory response. A subset of exosomes, called defensosomes, mediate host defense by binding and inhibiting pathogenic responses. A study showed that exosomes in SARS-CoV-2-infected patients can also be involved in this capacity by interfering with surface protein interactions [ 20 ]. Exosomes containing high levels of the viral receptor, ACE2, were induced from SARS-CoV-2 infection and activation of viral sensors in cell culture utilizing the autophagy protein, ATG16L1, and were shown to be able to bind and block viral entry. These findings support that exosomes may also be involved with the SARS-CoV-2 antiviral response, with more research of this area increasing our understanding of exosomes and their role in host defense mechanisms.
Finally, exosomes may provide insight into organ adaptations based on exosomes from the source organ, in general as well as in specific circumstances such as from viral infection. The exosomes produced from specific cells will communicate their cellular phenotypic state, with each exosome sharing the identity of its source cell. In turn, organ-specific adaptations from SARS-CoV-2 infection may be able to be delineated through measurement of exosomes. One study explored this by investigating how SARS-CoV-2 is known to invade neural cell mitochondria, with SARS-CoV-2 proteins and mitochondrial proteins contained within neuron- and astrocyte-derived exosomes quantified in post COVID-19 infection. Indeed, these exosomes contained SARS-CoV-2 N and S1 proteins and varied depending on the context of the disease severity and timeline of COVID-19 [ 21 ]. This study is one example of the utility exosomes may provide for complex, multi-organ conditions like COVID-19, in studying and determining physiological alterations resulting from the disease condition.
Roles of the non-coding transcriptome in SARS-CoV-2 infection
RNA viruses such as SARS-CoV-2 are flexible in their ability to circumvent cellular defenses through a variety of mechanisms that often involve specific interactions with cellular components. Additionally, some viral genomes can also be processed by cellular machinery to generate non-coding RNAs (ncRNAs) that could have regulatory functions. Among them, specific elements of the host ncRNA transcriptome include microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), have been described as important players in the regulation of the viral replicative cycle and the cellular antiviral responses (Fig. 1 ). To summarize the current knowledge about ncRNAs and SARS-CoV-2, we share the latest details of the different ncRNA families and their regulatory roles during infection and disease progression.
Structure and description of different categories of RNA involved in COVID-19.
We begin with highlighting microRNAs (miRNAs), which are short regulatory non-coding RNAs generated by the enzymatic processing of specific RNA transcripts. Their regulatory functions at the cellular level are exerted by recruiting regulatory proteins (RNA-induced silencing complex, or RISC) which are further targeted to the 3′-UTR of mRNAs by base complementarity, causing a repressive effect on gene expression [ 22 ]. Considering the possible involvement of dysregulated miRNAs upon infection on the systemic manifestations of COVID-19, multiple research groups profiled circulating miRNA levels in SARS-CoV-2 patients. One study of a stratified cohort of COVID-19 patients showed a molecular signature composed of three blood-circulating miRNAs (hsa-miR-423-5p, hsa-miR-23a-3p and hsa-miR-195-5p), independently classified COVID-19 cases, distinguishing them from other viral infections such as H1N1 influenza and healthy controls [ 23 ].
Recently a circulating miRNA, hsa-miR-2392, was shown and suggested to be one of the main drivers of a suppressive effect of mitochondrial gene expression and inflammation effectors, promoting many of the described symptoms associated with COVID-19. This miRNA was also detected in SARS-CoV-2-infected patient serum and urine, opening the possibility of its use as a prognostic biomarker for the disease [ 24 ]. Mitochondrial analysis showed miR-2392 targets were OXPHOS, mitochondrial translation, and mitochondrial metabolism related transcripts. In summary, SARS-CoV-2 elevates miRNAs, such as miR-2392, which can result in affecting biochemical pathways (e.g., downregulation of OXPHOS), and treatment with anti-miR-2393 therapeutics potentially blocks SARS-CoV-2 infection in hamsters and hACE2-A549 cells [ 24 ].
Several additional miRNA’s have also been observed to be involved with COVID-19 outcomes (e.g., level of viral load, biomarkers, etc.), as well as having various biochemical roles (e.g., viral entry, cytokine storm development, activation of signaling pathways, etc.). These include miRNA interaction with cell death processes, regulating pathways such as p53 by miR-101, miR-100, miR-7, miR-107, etc., as well with the viral entry process (e.g., hsa-miR-98-5p binding to TMPRSS2 transcript). Additionally, cellular inflammation processes in COVID-19 infected individuals are affected by miRNA’s (e.g., miR-146a, miR-21, and miR-142), by promoting MAPK and NF-kB signaling causing cellular pro-inflammatory phenotypic adaptations, which has additional consequences such as mitochondrial stress from production of inflammatory factors and reactive oxygen species. These highlight the significant and diverse roles miRNA’s play in steady-state physiology and viral infection induced pathophysiology in COVID-19, which here we briefly describe, but are covered in more detail in the following review [ 25 ].
Long non-coding RNAs (lncRNAs) are a wide family of non-coding transcripts characterized by their lack of coding potential, their larger sizes when compared to other ncRNAs (more than 200 nucleotides), and their origin from devoted transcriptional units. Functionally, lncRNAs can regulate the dynamics of the genomic output from chromatin to the cytoplasm, mainly by acting as molecular scaffolds of biological complexes that establish interactions with proteins, DNA, and other RNA molecules. Early transcriptomic studies using cell models show SARS-CoV-2 infection induces a transcriptional pattern that produces several differentially expressed lncRNAs [ 26 ]. Through co-expression network analysis, another study identified four differentially expressed lncRNAs correlating with genes involved in various immune-related pathways, suggesting that the aberrant expression of these four lncRNAs can be associated with SARS-CoV-2 cytokine storms and antiviral responses [ 27 ]. A different study using nasopharyngeal swabs from infected patients characterized an lncRNA, LASI, that is antisense to the ICAM-1 gene and had an expression profile strongly correlating with SARS-CoV-2 viral loads. LASI’s mechanism of action was shown to be through its interaction with the viral genome and subsequent knock-down of viral replication processes, which also resulted in the presence of inflammation markers [ 28 ]. In another study, a pattern of lncRNAs (NRIR, BISPR, and MIR155HG) was observed from nasopharyngeal COVID-19 patient samples that correlated with viral loads [ 29 ]. Interestingly, NRIR and BISPR lncRNAs were also upregulated in the blood of COVID-19 patients as reported in the COVIDOME project [ 30 ], suggesting possible involvement in the systemic manifestations of the viral infection.
Circular RNAs (circRNAs) are covalently closed RNA molecules generated by non-canonical back-splicing events from coding and non-coding transcripts. Several studies on the role of circRNAs in viral infections, such as SARS-CoV-2, have been published recently; however reports showing the involvement and function of circRNAs with SARS-CoV-2 infection are few and need to be considered with caution due to the limited number of samples and the intrinsic characteristics of the infection models. In one example, a lung epithelial cell model infected with SARS-CoV-2 showed differential circRNA expression upon infection. Analyzing these circRNA parental genes revealed they were involved with inflammation and immune responses [ 31 ]. CircRNAs related to SARS-CoV-2 infection have also been shown to be detectable in the peripheral blood circulation, highlighting their potential as COVID-19 biomarkers [ 32 ].
In this section, we describe humoral factors (and in the previous, metabolism related components) involved in steady-state physiology and responding to SARS-CoV-2 infection in COVID-19 patients, with these intrinsically affecting organ structure and function, and extrinsically affecting systemic physiology based on their production, secretion, and distribution through the circulatory system (Fig. 2 ). The circulatory system, part of the cardiovascular system, in of itself adapts to SARS-CoV-2 infection, which we will describe in the next section.
An overview of the processes involved with SARS-CoV-2 infection and replication that lead to cellular adaptations (see ref. [ 3 ] for more details) and extracellular release of various biological factors into the circulation causing systemic physiological effects.
Cardiovascular adaptations and changes
The cardiovascular system includes the heart, arteries, veins, capillaries, and lymphatics, which are the organ systems responsible for the transport of blood, lymph, and their constituents to every organ in the body. Blood and lymph transport multiple components, including water, red blood cells, white blood cells, macromolecules (e.g., lipids, proteins, carbohydrates, macromolecule, etc.), micromolecules (e.g., nutrients, ions, etc.), of which are circulated systemically and transported to and from all organs of the body. Included in the transport of these components by blood and lymph are pathogens, such as the SARS-CoV-2 virus, which benefits from the cardiovascular system not only by binding to a cell-type expressing its cognate receptor (e.g., endothelial cells and ACE2 receptor), but also from the cardiovascular system’s function in transporting the virus and its replicants away from the host infected cell, tissue, and organ. In turn, the COVID-19 cardiovascular-related symptoms vary greatly, ranging from asymptomatic or mild respiratory symptoms to severe life-threatening respiratory and cardiac failure [ 33 ].
Early reports have described common symptoms of COVID-19 to include fever (88%), fatigue (38%), chills (11%), headache (14%), nasal congestion (5%), sore throat (14%), dry cough (68%), dyspnea (19%), nausea/emesis (5%), diarrhea (4–14%), and myalgias (15%). A meta-analysis of eight studies showed a higher prevalence of hypertension (17 ± 7%) and diabetes mellitus (8 ± 6%) followed by cardiovascular disease (5 ± 4%) in COVID-19 patients [ 33 , 34 ]. Moreover, concomitant cardiovascular (CV) conditions may be occurring in 8–25% of COVID-19 infected population and an even greater proportion of those who die from the disease [ 33 ]. Indeed, evidence suggests that among the primary causes of death and overall mortality from COVID-19 infection are cardiac issues and respiratory failure [ 34 ].
These symptoms result from changes occurring at the molecular level from SARS-CoV-2 infection. A large autopsy study investigating multiple organs (heart, lung, kidney, liver, and lymph nodes) showed that the cellular and functional gene signatures from each organ’s major cell types (e.g., cardiomyocytes in the heart) decrease as a function of the viral load. More specifically in the heart ( n = 41 from patient autopsy samples), despite no histological change, many heart functional markers (e.g., TNNI3, TNNT2, MYBPC3, PLN, and HAND1) showed decreased levels resulting from COVID-19 infection [ 35 ]. Another study showed the presence of SARS-CoV-2 in the myocardial heart tissue from autopsy cases, suggested to be tied to myocardial injury [ 36 ]. Indeed, these cellular adaptations extend into the vascular system (e.g., arteries, veins, etc.), with histopathological evidence from autopsy studies showing direct viral infection of endothelial cells and micro- and macrovascular thrombosis occurring in both the arterial and venous circulations. An autopsy study investigating COVID-19 in three patients showed SARS-CoV-2 viral components present in the endothelial cells from different autopsied organs, including the kidney, lung, heart, and liver were each infected with SARS-CoV-2 [ 37 ]. Inflammation of the endothelium was also observed, along with recruitment of neutrophils and mononuclear cells to the site of damage. In vitro studies also support SARS-CoV-2 being able to directly infect cardiovascular cells as seen from experiments showing viral infection of engineered human blood vessel organoids [ 38 ]. Severe COVID-19 has also been associated with endothelial specific changes and effects such as elevated endothelial activation, hypercoagulability, and increased presence of von Willebrand Factor [ 39 , 40 ]. Endotheliitis from COVID-19 can occur, leading to a loss of cell–cell junctions, loss of endothelial cells, exposure of the basement membrane, abnormal cytokine release, abnormal reactive oxygen species release, and intussusceptive angiogenesis. Endothelin-1 has been suggested as a possible biomarker for those at risk with COVID-19 [ 34 ].
These cardiovascular adaptations from SARS-CoV-2 infection lead to a number of pathophysiological consequences including hypoxia, with prolonged ischemia leading to formation of hypoxanthine as an ATP breakdown product [ 36 ]. These effects may be from tissue remodeling caused by viral infection, as well as changes in blood viscosity, clotting, or inflammation, though more research of these areas would benefit our understanding of the effects of SARS-CoV-2 on the cardiovascular system and organ remodeling [ 33 , 34 , 36 ]. For example, a meta-analysis showed there are diverse cardiovascular complications including cardiac injury (e.g., myocardial injury, microinfarcts), heart failure, microembolic infarcts, acute coronary syndrome, arrhythmia, hypertension, and atrial and ventricular complications (e.g., fibrosis) [ 33 , 34 ]. Autopsy and case reports from COVID-19 patients are also varied in their observations of cardiac tissue changes, highlighting the complexity of the disease and individual differences influencing pathophysiological progression and outcomes. Identifying cardiovascular specific biomarkers would help evaluate, as well as measure progression of disease, with troponin I as one example of a clinical marker evaluating myocardial injury is troponin I. Troponin I has been shown to be elevated in >10% of patients hospitalized with COVID-19, increasing with disease severity [ 41 ]. Identifying more markers with cardiovascular specific outcomes (i.e. metabolites, lipids, humoral factors, etc., mentioned in the above sections) would help evaluate, correlate, and triage patients and improve their outcomes, as well as facilitate identification of specific biochemical pathways that may mechanistically explain disease symptoms.
Indeed, with the metabolic and physiological adaptations seen with COVID-19 patients, understanding mitochondrial adaptations in these contexts is relevant, given mitochondrial function in bioenergetics. As discussed in our first review, the mitochondria is heavily dysregulated and suppressed in the host during SARS-CoV-2 infection [ 3 ]. One study specifically analyzed transcriptomic data on heart samples collected from deceased COVID-19 patients [ 6 ]. This analysis showed heavy suppression at the transcript level of the majority of mitochondrial pathways and genes [ 6 ]. The non-coding transcriptome response to SARS-CoV-2 may also play a significant response and regulatory role with the cardiovascular adaptations developing from COVID-19 disease. Whether miRNA’s (e.g., hsa-miR-2392), lncRNA’s (e.g., NRIR and BISPR), or circRNA’s that are involved in suppressing mitochondrial gene expression, changing oxidative phosphorylation, mitochondrial structure (e.g., translation, metabolism, etc.), and causing inflammatory effects, may be involved with local cardiac adaptations or systemic vascular adaptations is unknown, but warrants future investigations to explore the specific roles of the transcriptome with cardiovascular adaptations. Furthermore, given the changes in cardiovascular structure, function, biochemical adaptations, that occur from SARS-CoV-2 infection, further study of cardiovascular mitochondrial adaptations is of relevance, and would help elucidate the underlying mechanisms impacting the cardiovascular system resultant from SARS-CoV-2 infection.
Immune adaptations and changes
The immune system includes the innate and adaptive immune systems. The innate system involves nonspecific responses to injury, and includes cell populations such as monocytes, macrophages, neutrophils, basophils, eosinophils, etc. The adaptive immune system involves specific response to pathogen infection, and includes cell populations such as T and B cells. The two arms of the immune system communicate, interact, and support each other in responding to injury, aided by humoral, circulating factors such as cytokines and chemokines, that provide information and context to immune cells as to how, where, and what to respond to, as well as the magnitude of the response. In turn, there are various feedback loops that provide guidance and direction to the immune system, both innate and adaptive, with SARS-CoV-2 activating both the innate and adaptive immune systems.
For the innate immune system, activation appears to be guided by neutrophils, which display increased levels of ROS and activated NETosis [ 42 ]. Additionally, the loss of ACE2 and DABK in the lungs of patients encourages neutrophil infiltration and inflammation. SARS-CoV-2 has also been suggested to dysregulate type 1 interferon signaling, which contributes to immune evasion early in infection. Consistent with this finding, bulk analysis of whole blood cell transcriptomes of severe COVID-19 patients compared with non-critically ill COVID-19 patients showed upregulation of Interferon alpha as the primary contributor to severe COVID-19. Activated monocytes and macrophages also migrate to the lungs (chemotaxis), further exacerbating lung inflammation and pulmonary fibrosis [ 43 ]. Several studies have reported disordered structure of the infected lung, along with extensive immune infiltration [ 35 , 44 ]. For example, the lung alveoli in COVID-19 patients develop additional hyaluronan, forming a coating that can reduce oxygen exchange, as well as leading to pulmonary edema. Another study of COVID-19 patients showed chronic lung impairment accompanied by persistent respiratory immune alterations, showing specific memory T and B cells enriched at the site of infection [ 45 ]. With the significant neutrophil, macrophage, T and B cell infiltration and activation observed, and localized hyperinflammatory states of these immune cells around alveolar epithelial cells, this develops into more lung damage and loss of compartmental identity. When a timeline and pattern of the cytokine storm in tracheal aspirate samples was organized and reported, divergences in the systemic versus airway cytokine production during COVID-19 were observed [ 46 ]. Indeed, a study assessing lung function of critical COVID-19 patients showed 55% of them experienced persistent impairment three months after ICU discharge, including declines in patient lung function, exercise capacity, and quality of life [ 47 ]. This suggests respiratory failure is another significant factor involved with patient mortality with severe SARS-CoV-2 infection, with an investigation of single-nuclei RNA sequencing of COVID-19 patient lung samples identified substantial alterations in cellular composition, transcriptional cell states, and cell-to-cell interactions, with the data showing COVID-19 patient lungs were highly inflamed, with dense infiltration of aberrantly activated macrophages, though with impaired T-cell responses and suggestions of impaired lung regeneration, based on alveolar type 1 cell phenotypes [ 48 ].
With regard to adaptive immune cell responses to SARS-CoV-2, these include lymphopenia (lowered CD4 and CD8 T-cell number) in COVID-19 patients, also seen in autopsy reports [ 49 , 50 ]. There are case by case variations; for example, an influx of T cells and myeloid cells occurs into the myocardium. In response to this event, COVID-19’s pathogen-associated molecular patterns and damage-associated molecular patterns (PAMPs and DAMPs) are activated, as well as cytokines released by alveolar macrophages [ 51 , 52 ]. These pathways are thought to contribute to the dysregulation of monocytes and macrophages in COVID-19 [ 53 ] and the subsequent dysfunction of T cells. Changes also occur within the heart, as seen with gene expression analysis of cardiac tissue for TNF-ɑ, interferon-γ, chemokine ligand 5, interleukin-6, interleukin-8 (CXCL8), and interleukin-18. Severe COVID-19 is also associated with elevated endothelial activation, hypercoagulability, and the presence of von Willebrand Factor (vWF) [ 53 , 54 ]. Indeed, COVID-19 induces a complex pattern of cytokine release as part of an overall dysregulated immune response that, in severe cases, injures the parenchyma of vital organs and leads to viremia and sepsis [ 55 , 56 ].
Severe COVID-19 is characterized by an inflammatory profile that involves initial immune evasion by downregulation of Type I Interferon pathways along with significant upregulation of IL-6, IL-8 and TNF-α in the lungs that coincides with increased NF-κB activity [ 57 , 58 ]. In one study of COVID-19 patients, a notable increase in multiple serum cytokines (e.g., TNF-α, IFN-γ, IL-2, IL-4, IL-6 and IL-10) was seen [ 59 ], while another study showed high plasma levels of IL-1 β , IL-1RA, IL-7, IL-8, IL-9, IL-10, bFGF, GCSF, GM-CSF, IFN-γ, IP-10, MCP1, MIP-1α, MIP-1 β , PDGF, TNF-α, and VEGF. A different study showed increased levels of inflammatory markers such as C-reactive protein, D-dimer, ferritin, IL-6 and lactate dehydrogenase (LDH) associated with higher mortality in COVID-19 patients [ 60 ]. These results suggest an overproduction of cytokines in response to lung damage, or as a compensatory response to attempt to re-direct, accelerate, or shutdown the immune response. These cytokine fluctuations also coincide with systemic inflammation and myocardial injury; in 137 patients admitted for COVID-19 disease in Hubei province, heart palpitations were noted as one of the presenting symptoms in 7.3% of patients [ 61 ]. Moreover, there have been reports of complete heart blockage and atrial fibrillation in patients with COVID-19 infection [ 62 ]. In patients diagnosed with severe COVID-19, increased levels of pro-inflammatory cytokines, (e.g., soluble IL-2R, IL-6, IL-8, and TNF-α) have been observed, with these cytokines disrupting endothelial cells antithrombotic and anti-inflammatory functions, leading to coagulation dysregulation, complement and platelet activation, and leukocyte recruitment in the microvasculature [ 63 , 64 ]. While increased levels of circulating chemokines, pro-inflammatory cytokines, regulatory cytokines, and growth factors were observed in severe COVID patients who died as compared to surviving patients, a more restricted and selective increase of cytokines such as IL-10 was observed in the airway samples with actual decreased levels of pro-inflammatory cytokines such as IFN-γ, IL-17, IL-5, and IL-2 as compared to uninfected controls [ 46 ]. These results demonstrate that inflammation is also highly modulated in the airways as an attempt to decrease exacerbated inflammation. Figure 1 illustrates a snapshot of extracellular factors involved with immune adaptations during COVID-19 and the uniqueness of systemic versus airway inflammatory milieu.
Organ alterations from SARS-CoV-2 infection
In addition to the cardiovascular system, SARS-CoV-2 infects and has an effect on many organ systems (e.g., cardiovascular, immune, and endocrine systems, as described above), including the lungs, lymph nodes, brain, liver, kidneys, gastrointestinal tract, testis (Fig. 3 ) [ 65 , 66 , 67 ]. COVID-19 is known to cause multi-organ dysfunction, though the burden of infection outside the respiratory tract and time to viral clearance is not well understood. A recent postmortem study of 44 patients quantified and mapped the distribution, replication, and cell-type specificity of SARS-CoV-2 across the body, specifically the brain but other organs as well, from acute infection to more than seven months following symptom onset. It was seen that SARS-CoV-2 infection of the body was widely spread across respiratory and non-respiratory tissues (e.g., the brain) [ 68 ]. This spread of infection provides context for the different symptoms patients experience.
An overview of the systemic organ adaptations resulting from SARS-CoV-2 infection as well as symptoms that develop.
Neurological and psychiatric symptoms have been reported for acute, post-acute, and longer-term SARS-CoV-2 infection in human patients across the human lifespan [ 69 ]. Although neurological manifestations remain incompletely characterized in terms of etiology, severity, and incidence, they present signs of nonspecific (e.g., headache, dizziness, myalgia, fatigue, somnolence, insomnia, etc.) and specific (e.g., encephalopathy, encephalitis, stroke, status epilepticus, ataxia, anosmia, ageusia, demyelinating syndromes, etc.) deficits of the central nervous system, the peripheral nervous system, or both, with new-onset or relapsed associated prodromal, subthreshold, or fully expressed (i.e., suprathreshold) psychiatric conditions. The spectrum of presumed virogenic psychiatric disorders across age cohorts and other demographic classifications is broad and includes anxiety, depression, confusion or disordered thought (e.g., brain fogor psychosis). Structural and functional changes in brain anatomy, such as brief to protracted alterations in gray and white matter volume, blood perfusion and oxygenation, and metabolic activity [ 70 ], often parallel and are consistent with onset and duration of mental health diagnoses in infected populations. Areas caudal to the neocortex tend to be most affected, with olfactory cortex, basal ganglia, hippocampus, amygdala, cerebellum, and brain stem abnormalities occurring in greater frequency and magnitude in COVID-19 patients. Uncertainty regarding the cause of COVID-19-related neuropathology centers on SARS-CoV-2 neuroinvasion, with the olfactory epithelium as a plausible entry point with subsequent retrograde transsynaptic propagation to other brain areas.
Astrocytes and Schwann cells infected by SARS-CoV-2 may also be negatively impacted with their neurotransmission, synapse modulation, reinnervation, metabolite and electrolyte homeostasis, and cell signaling functions. This may cause, contribute, or lead to observed central and peripheral nervous system trauma and dysfunction [ 70 ]. There is data that also supports hematogenous mechanisms enabling viral access to nervous tissue through infection of blood-brain-barrier (BBB) endothelial cells or epithelial cells of the choroid plexus blood–CSF barrier. Indeed, a study examining SARS-CoV-2 interaction with brain organoids suggests a compromised blood-brain-barrier (BBB) as manifested by injured endothelial cells and increased BBB permeability [ 71 ]. Multisystem hyperinflammatory immunoreactions most appropriately describe for the diverse set of pathologies observed in post mortem autopsy analyses, as well as in live in vivo or in vitro tissue, the result of hemorrhagic, ischemic, and hypoxic injury, mitochondrial dysfunction, neuronal damage and apoptosis, and microglial and astrocytic activation.
With regard to gastrointestinal (GI) effects of SARS-CoV-2, an autopsy study of 29 cases showed the GI to be one of the primary organs infected by the virus, as well as being supported by the literature of postmortem organ analysis [ 65 ]. GI involvement and symptoms (e.g., diarrhea, anorexia, nausea/vomiting, abdominal pain, etc.) is associated with long hospital stays and severity of disease, with the rates of GI symptoms of the percent of individuals ranging from 11% to 53%. ACE2 is frequently found in human intestinal epithelial cells, with SARS-CoV-2 being detected in patient GI samples [ 72 ]. Indeed, while there is a paucity of data of SARS-CoV-2 effects on GI physiology, GI symptoms are common in patients with COVID-19, though and should be considered when evaluating patient conditions as well as treatment options.
Here we summarize a few examples of organ adaptations resulting from SARS-CoV-2 infection. These highlight the virus’s diverse biological targets and outcomes, though more studies are warranted given our comprehensive lack of understanding of these, and other, organ alterations, as well in particular, the biochemical pathways that are affected by viral infection. In addressing these knowledge gaps, patient care will improve as well as new treatment modalities will be identified. Moreover, these adaptations are related with long-term implications of SARS-CoV-2 infection, of which we describe in the next section.
Impact of circulating factors on post-acute sequelae of SARS-CoV-2 (PASC, long COVID-19)
In addition to COVID-19 from SARS-CoV-2 infection, patients may experience long-term symptoms as a result of organ or tissue damage due to SARS-CoV-2. This condition is referred to as post-acute sequelae of SARS-CoV-2 (PASC), or long COVID-19 [ 73 , 74 ]. PASC patients are burdened with multiple symptoms, including more than a third of PASC patients continuing to experience lung fibrotic abnormalities following hospital discharge [ 75 ]. Many are also at risk of developing microemboli due to maladaptations with clotting physiology (e.g., massively increased levels of vWF which leads to increased platelet activation, etc.) [ 76 ]. Indeed, virus-driven cellular alterations have been suggested to contribute to the pathophysiology of PASC patients [ 3 , 77 ]. Persistent viral presence and inflammation within the olfactory epithelium has been evident from histological analysis, as well as long-term impairments in taste and smell in the cells of the tongue’s taste buds [ 78 ].
PASC is also characterized by chronic fatigue, which has numerous underlying causes. As a comparison, the post-flu or fever fatigue that occurs (e.g., Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)) may have some similarities to the persistent fatigue in PASC. PASC symptoms may also be influenced by abnormalities of the central nervous system, such as brain hypometabolism [ 79 ]. A recent postmortem study also quantified and mapped the SARS-CoV-2 organ tropism, finding long-term signs of infection in the brain, as well as across the body within the tissue (e.g., respiratory, cardiovascular, lymphoid, gastrointestinal, genitourinary, endocrine, skin, and peripheral nervous systems) seven months following infection onset, confirmed through in situ hybridization, immunohistochemistry, and immunofluorescence analyses of the tissue, isolation of SARS-CoV-2 from tissue by cell culture, and detection of the spike sequence variants in non-respiratory sites [ 71 ]. While psychological and environmental factors are likely to be involved, long-term biochemical adaptations, including increased oxidative stress and muscle mitochondrial failure, may contribute to the chronic fatigue syndrome found in PASC patients [ 80 ]. In addition, due to the activation of the fibrosis pathway from persistent virus-induced inflammation, the heart may subsequently undergo structural remodeling that may also explain the PASC symptoms [ 81 ]. There are also long-term immune changes, with PASC patients having elevated expression of type I IFN (IFN-) and type III IFN (IFN-1), highly activated innate immune cells, while lacking naive T and B cells [ 82 ], which may also be related with the symptoms PASC patients experience, but also increase their risk of infection, etc.
Indeed, while many individuals recover from SARS-CoV-2, a significant number of patients continue to suffer with long-term disease symptoms (e.g., PASC) long term after recovery from the primary infection [ 73 , 74 ]. The severity of the primary infection appears to be independent from the possibility and severity of long-term symptoms, though this requires further research. Indeed, it is critical to understand the systemic effects of PASC, its biological mechanism and symptoms, and to develop treatments that promote functional recovery in symptomatic individuals, given the negative health-effects of PASC, as well as the socioeconomic and healthcare burden this condition will impose. Further research on PASC will improve our knowledge and understanding of the condition, as well as enable identification of relevant treatments and interventions to improve patient outcomes.
SARS-CoV-2 and its resultant acute and chronic diseases, COVID-19 and PASC, have caused significant impacts worldwide. Here we describe and review the latest knowledge about the viral effect on our physiology, as well as the latest research on relevant whole-body metabolism pathways, circulating biological components (e.g., RNA, cytokine, hormones, etc.), and affected organ systems and their physiological adaptations consequent to SARS-CoV-2 infection.
COVID-19 is a pleiotropic, complex, and dynamic condition (Fig. 4 ). The viral insults and cellular adaptations differ depending on the context, from cellular to organ systems, and intricate biochemistry ties and integrates these systems together. Herein, we have attempted to capture the prevalent host responses, as well as highlight gaps of knowledge that could be addressed with future research. We have also touched on relevant biochemical targets with potential for mitigating COVID-19 in the human host, and we will describe current and in-development treatment modalities that affect these in Part 3 of our review.
The multi-faceted and multiplex physiological adaptations resulting from SARS-CoV-2 infection, including the different cells, tissues, and organs that respond to viral infection. The airway milieu refers to the viral factors contained from inhalation and response to these factors in the lungs, while the systemic milieu refers to the viral factors transported through the circulation system and across body, and in turn, the physiological responses to these factors.
Rydland HT, Friedman J, Stringhini S, Link BG, Eikemo TA. The radically unequal distribution of Covid-19 vaccinations: a predictable yet avoidable symptom of the fundamental causes of inequality. Humanit Soc Sci Commun. 2022;9:1–16.
Jalali N, Brustad HK, Frigessi A, MacDonald EA, Meijerink H, Feruglio SL, et al. Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants. Nat Commun. 2022;13:5706.
Article CAS PubMed PubMed Central Google Scholar
Jamison DA Jr, Anand Narayanan S, Trovão NS, Guarnieri JW, Topper MJ, Moraes-Vieira PM, et al. A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection. Eur J Hum Genet. 2022;30:889–98.
Article PubMed PubMed Central Google Scholar
Prasad K, Khatoon F, Rashid S, Ali N, AlAsmari AF, Ahmed MZ, et al. Targeting hub genes and pathways of innate immune response in COVID-19: a network biology perspective. Int J Biol Macromol. 2020;163:1–8.
Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS ONE. 2009;4:e8342.
Guarnieri JW, Dybas JM, Fazelinia H, Kim MS, Frere J, Zhang Y, et al. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts. Sci Transl Med. 2023;15:eabq1533.
Article CAS PubMed Google Scholar
Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182:59–72.
Cheng ZJ, Yang X, Wang H. Hyperhomocysteinemia and endothelial dysfunction. Curr Hypertens Rev. 2009;5:158–65.
Barberis E, Timo S, Amede E, Vanella VV, Puricelli C, Cappellano G, et al. Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to SARS-CoV-2. Int J Mol Sci. 2020;21:8623.
Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, et al. Severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome resulting in dysregulation of eicosanoid immune mediators. J Immunol. 2021;206:329.
Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI insight. 2020;5:e140327.
Tanner JE, Alfieri C. The fatty acid lipid metabolism nexus in COVID-19. Viruses. 2021;13:90.
Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. elife. 2020;9:e59177.
Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the endocrine system: a mini-review. Endocrinology. 2022;163:bqab203.
Article PubMed Google Scholar
Lazartigues E, Qadir MM, Mauvais-Jarvis F. Endocrine significance of SARS-CoV-2’s reliance on ACE2. Endocrinology. 2020;161:bqaa108.
Kitsou K, Kotanidou A, Paraskevis D, Karamitros T, Katzourakis A, Tedder R, et al. Upregulation of human endogenous retroviruses in bronchoalveolar lavage fluid of COVID-19 patients. Microbiol Spectr. 2021;9:e01260–21.
Alfaro E, Díaz-García E, García-Tovar S, Zamarrón E, Mangas A, Galera R, et al. Impaired kallikrein-kinin system in COVID-19 patients’ severity. Front Immunol. 2022;13:909342.
Sur S, Steele R, Isbell TS, Ray R, Ray RB. Circulatory exosomes from COVID-19 patients trigger NLRP3 inflammasome in endothelial cells. Mbio. 2022;13:e00951–22.
Pesce E, Manfrini N, Cordiglieri C, Santi S, Bandera A, Gobbini A, et al. Exosomes recovered from the plasma of COVID-19 patients expose SARS-CoV-2 spike-derived fragments and contribute to the adaptive immune response. Front Immunol. 2022;12:785941.
Ching KL, de Vries M, Gago J, Dancel-Manning K, Sall J, Rice WJ, et al. ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection. PLoS Biol. 2022;20:e3001754.
Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, et al. SARS‐CoV‐2 and mitochondrial proteins in neural‐derived exosomes of COVID‐19. Ann Neurol. 2022;91:772–81.
Leitão AL, Enguita FJ. A structural view of miRNA biogenesis and function. Noncoding RNA. 2022;8:10.
PubMed PubMed Central Google Scholar
Farr RJ, Rootes CL, Rowntree LC, Nguyen TH, Hensen L, Kedzierski L, et al. Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog. 2021;17:e1009759.
McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, et al. Role of miR-2392 in driving SARS-CoV-2 infection. Cell Rep. 2021;37:109839.
Panda M, Kalita E, Singh S, Kumar K, Rao A, Prajapati VK. MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies. Life Sci. 2022:120761.
Shaath H, Vishnubalaji R, Elkord E, Alajez NM. Single-cell transcriptome analysis highlights a role for neutrophils and inflammatory macrophages in the pathogenesis of severe COVID-19. Cells. 2020;9:2374.
Mukherjee S, Banerjee B, Karasik D, Frenkel-Morgenstern M. mRNA-lncRNA Co-expression network analysis reveals the role of lncRNAs in immune dysfunction during severe SARS-CoV-2 infection. Viruses. 2021;13:402.
Devadoss D, Acharya A, Manevski M, Houserova D, Cioffi MD, Pandey K, et al. Immunomodulatory LncRNA on antisense strand of ICAM-1 augments SARS-CoV-2 infection-associated airway mucoinflammatory phenotype. Iscience. 2022;25:104685.
Enguita FJ, Leitão AL, McDonald JT, Zaksas V, Das S, Galeano D, et al. The interplay between lncRNAs, RNA-binding proteins and viral genome during SARS-CoV-2 infection reveals strong connections with regulatory events involved in RNA metabolism and immune response. Theranostics. 2022;12:3946.
Sullivan KD, Galbraith MD, Kinning KT, Bartsch KW, Levinsky NC, Araya P, et al. The COVIDome explorer researcher portal. Cell Rep. 2021;36:109527.
Yang M, Qi M, Xu L, Huang P, Wang X, Sun J, et al. Differential host circRNA expression profiles in human lung epithelial cells infected with SARS-CoV-2. Infect, Genet Evol. 2021;93:104923.
Wu Y, Zhao T, Deng R, Xia X, Li B, Wang X. A study of differential circRNA and lncRNA expressions in COVID-19-infected peripheral blood. Sci Rep. 2021;11:7991.
Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19. JCI insight. 2021;6:e148980.
Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648–55.
Park J, Foox J, Hether T, Danko DC, Warren S, Kim Y, et al. System-wide transcriptome damage and tissue identity loss in COVID-19 patients. Cell Rep. Med. 2022;3:100522.
Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5:1281–5.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8.
Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–13.
Chang R, Mamun A, Dominic A, Le NT. SARS-CoV-2 mediated endothelial dysfunction: the potential role of chronic oxidative stress. Front Physiol. 2021;11:605908.
Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24:1–8.
Article Google Scholar
Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail. 2020;26:470–5.
Arcanjo A, Logullo J, Menezes CC, de Souza Carvalho Giangiarulo TC, Dos Reis MC, de Castro GM, et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). Sci Rep. 2020;10:19630.
Karki R, Lee S, Mall R, Pandian N, Wang Y, Sharma BR, et al. ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Sci Immunol. 2022;7:eabo6294.
Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, et al. The spatial landscape of lung pathology during COVID-19 progression. Nature. 2021;593:564–9.
Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, et al. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol. 2021;6:eabk1741.
Gonçalves JJ, da Mata CP, Lourenço AA, Ribeiro ÁL, Ferreira GM, Fraga-Silva TF, et al. Timeline kinetics of systemic and airway immune mediator storm for comprehensive analysis of disease outcome in critically ill COVID-19 patients. Front Immunol. 2022;13:903903.
Truffaut L, Demey L, Bruyneel AV, Roman A, Alard S, De Vos N, et al. Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. Respir Res. 2021;22:1–6.
Melms JC, Biermann J, Huang H, Wang Y, Nair A, Tagore S, et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595:114–9.
Singh Y, Trautwein C, Fendel R, Krickeberg N, Berezhnoy G, Bissinger R, et al. SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. Heliyon. 2021;7:e07147.
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–80.
Onofrio L, Caraglia M, Facchini G, Margherita V, Placido SD, Buonerba C. Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Sci OA. 2020;6:FSO605.
Patra R, Das NC, Mukherjee S. Targeting human TLRs to combat COVID‐19: a solution? J Med Virol. 2021;93:615.
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–62.
Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, et al. The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients. J Thromb Haemost. 2021;19:513–21.
Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:1–7.
Tan C, Li S, Liang Y, Chen M, Liu J. SARS-CoV-2 viremia may predict rapid deterioration of COVID-19 patients. Braz J Infect Dis. 2021;24:565–9.
Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021;34:1456–67.
Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9:1123–30.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. lancet. 2020;395:497–506.
Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133:1025–31.
Azarkish M, Laleh Far V, Eslami M, Mollazadeh R. Transient complete heart block in a patient with critical COVID-19. Eur Heart J. 2020;41:2131.
Chen G, Wu DI, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130:2620–9.
Pons S, Arnaud M, Loiselle M, Arrii E, Azoulay E, Zafrani L. Immune consequences of endothelial cells’ activation and dysfunction during sepsis. Crit Care Clin. 2020;36:401–13.
Yao XH, Luo T, Shi Y, He ZC, Tang R, Zhang PP, et al. A cohort autopsy study defines COVID-19 systemic pathogenesis. Cell Res. 2021;31:836–46.
Nobari NN, Montazer F, Seirafianpour F, Nikkhah F, Aryanian Z, Goodarzi A. Histopathologic changes and cellular events of organs systems in COVID-19. J Cell Mol Anesth. 2021;6:81–8.
Google Scholar
Shah MD, Sumeh AS, Sheraz M, Kavitha MS, Maran BA, Rodrigues KF. A mini-review on the impact of COVID 19 on vital organs. Biomed Pharmacother. 2021;143:112158.
Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758–63.
Stafstrom CE. Neurological effects of COVID‐19 in infants and children. Dev Med Child Neurol. 2022;64:818–29.
Crunfli F, Carregari VC, Veras FP, Silva LS, Nogueira MH, Antunes AS, et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci USA. 2022;119:e2200960119.
Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration. Sig Transduct Target Ther. 2021;6:337.
Article CAS Google Scholar
Livanos AE, Jha D, Cossarini F, Gonzalez-Reiche AS, Tokuyama M, Aydillo T, et al. Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms. Gastroenterology. 2021;160:2435–50.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15.
Crook H, Raza S, Nowell J, Young M, Edison P Long covid—mechanisms, risk factors, and management. BMJ. 2021;374:n1648.
de Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. COVID-19–related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021;13:eabf8396.
Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21:148.
Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473–87.
Vaira LA, Hopkins C, Sandison A, Manca A, Machouchas N, Turilli D, et al. Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. J Laryngol Otol. 2020;134:1123–7.
Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48:2823–33.
Wood E, Hall KH, Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’? Chronic Dis Transl Med. 2021;7:14–26.
PubMed Google Scholar
Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, et al. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect. 2021;83:1–6.
Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CM, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210–6.
Download references
Acknowledgements
The opinions expressed in this article are those of the authors and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, the National Science Foundation, or the United States government. APK’s research is supported by the Department of Defense and Swezey & Jewell, Moore and MacKenzie Research Fund.
This work was supported by supplemental funds for COVID-19 research from Translational Research Institute of Space Health through NASA Cooperative Agreement NNX16AO69A (T-0404) to AB, and by a NASA Space Biology Postdoctoral Fellowship (80NSSC19K0426) and Human Research Program Augmentation Award (80NSSC19K1322) to SAN.
Author information
These authors contributed equally: S. Anand Narayanan, David A. Jamison Jr.
Authors and Affiliations
COVID-19 International Research Team, Medford, MA, 02155, USA
S. Anand Narayanan, David A. Jamison Jr, Joseph W. Guarnieri, Victoria Zaksas, Michael Topper, Kevin B. Clark, Francisco J. Enguita, Saswati Das, Pedro M. Moraes-Vieira, Diego Galeano, Christopher E. Mason, Nídia S. Trovão, Robert E. Schwartz, Jonathan C. Schisler, Jordana G. A. Coelho-dos-Reis, Eve Syrkin Wurtele & Afshin Beheshti
Department of Health, Nutrition and Food Sciences, Florida State University, Tallahassee, FL, 32301, USA
S. Anand Narayanan
Center for Mitochondrial and Epigenomic Medicine, Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 19104, USA
Joseph W. Guarnieri
Center for Translational Data Science, University of Chicago, Chicago, IL, 60637, USA
Victoria Zaksas
Clever Research Lab, Springfield, IL, 62704, USA
Departments of Oncology and Medicine and the Sidney Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Michael Topper
Human Healthspan, Resilience, and Performance, Florida Institute for Human and Machine Cognition, Pensacola, FL, 32502, USA
Andrew P. Koutnik
Sansum Diabetes Research Institute, Santa Barbara, CA, 93015, USA
Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY, USA
Jiwoon Park & Christopher E. Mason
Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, 10065, USA
Jiwoon Park
Cures Within Reach, Chicago, IL, 60602, USA
Kevin B. Clark
Campus and Domain Champions Program, Multi-Tier Assistance, Training, and Computational Help (MATCH) Track, National Science Foundation’s Advanced Cyberinfrastructure Coordination Ecosystem: Services and Support (ACCESS), Philadelphia, PA, USA
Expert Network, Penn Center for Innovation, University of Pennsylvania, Philadelphia, PA, 19104, USA
Biometrics and Nanotechnology Councils, Institute for Electrical and Electronics Engineers, New York, NY, 10016, USA
Peace Innovation Institute, The Hague 2511, Netherlands and Stanford University, Palo Alto, 94305, CA, USA
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028, Lisboa, Portugal
Francisco J. Enguita
MEtRICs, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal
Ana Lúcia Leitão
Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Mannohar Lohia Hospital, New Delhi, 110001, India
Saswati Das
Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
Pedro M. Moraes-Vieira
Experimental Medicine Research Cluster (EMRC) and Obesity and Comorbidities Research Center (OCRC), University of Campinas, Campinas, Brazil
Facultad de Ingeniería, Universidad Nacional de Asunción, San Lorenzo, Paraguay
Diego Galeano
New York Genome Center, New York, NY, USA
Christopher E. Mason
The Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA
Fogarty International Center, National Institutes of Health, Bethesda, MD, 20892, USA
Nídia S. Trovão
Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA
Robert E. Schwartz
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA
McAllister Heart Institute and Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Jonathan C. Schisler
Basic and Applied Virology Lab, Department of Microbiology, Institute for Biological Sciences (ICB), Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
Jordana G. A. Coelho-dos-Reis
Genetics Program, Department of Genetics, Development and Cell Biology, Iowa State University, Ames, IA, 90011, USA
Eve Syrkin Wurtele
Bioinformatics and Computational Biology Program, Center for Metabolomics, Department of Genetics, Development and Cell Biology, Iowa State University, Ames, IA, 90011, USA
Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
Afshin Beheshti
Blue Marble Space Institute of Science, Space Biosciences Division, NASA Ames Research Center, Moffett Field, Santa Clara, CA, 94035, USA
You can also search for this author in PubMed Google Scholar
Contributions
Conceptualization: AB, and SAN; Original draft: SAN, DAJ, FJE, and AB; Review & editing: all authors; Figures and visualization: JCAC-d-R, SAN; Funding acquisition: SAN; Supervision: AB.
Corresponding authors
Correspondence to S. Anand Narayanan or Afshin Beheshti .
Ethics declarations
Competing interests.
RES is on the scientific advisory board of Miromatrix Inc and Lime Therapeutics and is a consultant and speaker for Alnylam Inc. The remaining authors declare no competing financial interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ .
Reprints and permissions
About this article
Cite this article.
Narayanan, S.A., Jamison, D.A., Guarnieri, J.W. et al. A comprehensive SARS-CoV-2 and COVID-19 review, Part 2: host extracellular to systemic effects of SARS-CoV-2 infection. Eur J Hum Genet 32 , 10–20 (2024). https://doi.org/10.1038/s41431-023-01462-1
Download citation
Received : 16 January 2023
Revised : 01 September 2023
Accepted : 13 September 2023
Published : 08 November 2023
Issue Date : January 2024
DOI : https://doi.org/10.1038/s41431-023-01462-1
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Quick links
- Explore articles by subject
- Guide to authors
- Editorial policies
- Introduction
- Observations
- Clinical Presentation
- Assessment and Diagnosis
- Disparities
- Prevention and Vaccine Development
- Conclusions
- Article Information
Based on data from World Health Organization (WHO) COVID-19 situation reports. The COVID-19 outbreak was first recognized in Wuhan, China, in early December 2019. The number of confirmed COVID-19 cases is displayed by date of report and WHO region. SARS-CoV-2 indicates severe acute respiratory syndrome coronavirus 2.
Current understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–induced host immune response. SARS-CoV-2 targets cells through the viral structural spike (S) protein that binds to the angiotensin-converting enzyme 2 (ACE2) receptor. The serine protease type 2 transmembrane serine proteas (TMPRSS2) in the host cell further promotes viral uptake by cleaving ACE2 and activating the SARS-CoV-2 S protein. In the early stage, viral copy numbers can be high in the lower respiratory tract. Inflammatory signaling molecules are released by infected cells and alveolar macrophages in addition to recruited T lymphocytes, monocytes, and neutrophils. In the late stage, pulmonary edema can fill the alveolar spaces with hyaline membrane formation, compatible with early-phase acute respiratory distress syndrome.
A, Transverse thin-section computed tomographic scan of a 76-year-old man, 5 days after symptom onset, showing subpleural ground-glass opacity and consolidation with subpleural sparing. B, Transverse thin-section computed tomographic scan of a 76-year-old man, 21 days after symptom onset, showing bilateral and peripheral predominant consolidation, ground-glass with reticulation, and bronchodilatation. C, Pathological manifestations of lung tissue in a patient with severe pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) showing interstitial mononuclear inflammatory infiltrates dominated by lymphocytes (magnification, ×10). D, Pathological manifestations of lung tissue in a patient with severe pneumonia caused by SARS-CoV-2 showing diffuse alveolar damage with edema and fibrine deposition, indicating acute respiratory distress syndrome with early fibrosis (magnification, ×10). Images courtesy of Inge A. H. van den Berk, MD (Department of Radiology, Amsterdam UMC), and Bernadette Schurink, MD (Department of Pathology, Amsterdam UMC).
Eric Topol, MD, Scripps Research EVP and omnivorous science health care and tech commentator, discusses the evolving COVID-19 pandemic. Recorded July 23, 2020.
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) JAMA Review May 12, 2020 This narrative review summarizes what is currently known about how SARS-CoV-2 infects cells and causes disease as a basis for considering whether chloroquine, remdisivir and other antivirals, or other existing drugs might be effective treatment for coronavirus disease 2019 (COVID-19). James M. Sanders, PhD, PharmD; Marguerite L. Monogue, PharmD; Tomasz Z. Jodlowski, PharmD; James B. Cutrell, MD
- Ensuring Scientific Integrity and Public Confidence in the Search for Effective COVID-19 Treatment JAMA Viewpoint May 19, 2020 This Viewpoint discusses the risks to patients and public health posed by the FDA’s politically pressured Emergency Use Authorization (EUA) of chloroquine and hydroxychloroquine for COVID-19 treatment, and proposes principles to follow to ensure new therapies are studied properly and quickly to maximize benefits and minimize risks to patients. Jesse L. Goodman, MD, MPH; Luciana Borio, MD
- Monoclonal Antibodies for Prevention and Treatment of COVID-19 JAMA Viewpoint July 14, 2020 This Viewpoint discusses the potential role of neutralizing monoclonal antibodies (MAbs) as a treatment for coronavirus disease 2019 (COVID-19) and as a means of prevention in high-risk populations, and it also raises possible limitations of the approach that need to be disproven or addressed for the strategy to be effective. Mary Marovich, MD; John R. Mascola, MD; Myron S. Cohen, MD
- Presence of Genetic Variants Among Young Men With Severe COVID-19 JAMA Preliminary Communication August 18, 2020 This case series describes rare putative X-chromosomal loss-of-function variants associated with impaired peripheral mononuclear blood cell interferon signaling in 4 young male patients hospitalized with severe coronavirus disease 2019 (COVID-19) in the Netherlands. Caspar I. van der Made, MD; Annet Simons, PhD; Janneke Schuurs-Hoeijmakers, MD, PhD; Guus van den Heuvel, MD; Tuomo Mantere, PhD; Simone Kersten, MSc; Rosanne C. van Deuren, MSc; Marloes Steehouwer, BSc; Simon V. van Reijmersdal, BSc; Martin Jaeger, PhD; Tom Hofste, BSc; Galuh Astuti, PhD; Jordi Corominas Galbany, PhD; Vyne van der Schoot, MD, PhD; Hans van der Hoeven, MD, PhD; Wanda Hagmolen of ten Have, MD, PhD; Eva Klijn, MD, PhD; Catrien van den Meer, MD; Jeroen Fiddelaers, MD; Quirijn de Mast, MD, PhD; Chantal P. Bleeker-Rovers, MD, PhD; Leo A. B. Joosten, PhD; Helger G. Yntema, PhD; Christian Gilissen, PhD; Marcel Nelen, PhD; Jos W. M. van der Meer, MD, PhD; Han G. Brunner, MD, PhD; Mihai G. Netea, MD, PhD; Frank L. van de Veerdonk, MD, PhD; Alexander Hoischen, PhD
- Strongyloides Hyperinfection Risk in COVID-19 Patients Treated With Dexamethasone JAMA Viewpoint August 18, 2020 Anticipating widespread global use of dexamethasone for COVID-19 in the wake of RECOVERY trial findings, this Viewpoint summarizes the theoretical risk of triggering Strongyloides hyperinfection/dissemination syndrome in people with asymptomatic strongyloidiasis, and proposes an algorithm to for assessing and managing the risk in outpatient and hospital settings. William M. Stauffer, MD, MSPH; Jonathan D. Alpern, MD; Patricia F. Walker, MD, DTM&H
- Patient Information: COVID-19 JAMA JAMA Patient Page August 25, 2020 This JAMA Patient Page provides an overview of COVID-19 transmission, symptoms, diagnosis, disease course, and treatment. W. Joost Wiersinga, MD, PhD, MBA; Hallie C. Prescott, MD, MSc
- Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions JAMA Research Letter October 20, 2020 This study compares levels of tumor necrosis factor α, IL-6, and IL-8 in critically ill patients with coronavirus disease 2019 (COVID-19) vs those with other critical illness to better characterize the contribution of cytokine storm to COVID-19 pathophysiology. Matthijs Kox, PhD; Nicole J. B. Waalders, BSc; Emma J. Kooistra, BSc; Jelle Gerretsen, BSc; Peter Pickkers, MD, PhD
- Racial/Ethnic Variation in Nasal Transmembrane Serine Protease 2 ( TMPRSS2 ) Gene Expression Facilitating Coronavirus Entry JAMA Research Letter October 20, 2020 This cross-sectional study used nasal epithelium collected in 2015-2018 to compare expression of TMPRSS2, a facilitator of SARS-CoV-2 viral entry and spread, among Asian, Black, Latino, and White patients as well as patients of mixed race/ethnicity within a New York City health system. Supinda Bunyavanich, MD, MPH, MPhil; Chantal Grant, MD; Alfin Vicencio, MD
- Therapy for Early COVID-19—A Critical Need JAMA Viewpoint December 1, 2020 In this Viewpoint, Fauci and NIAID colleagues review leading candidates for treatment of mild to moderate coronavirus disease 2019 (COVID-19) to prevent disease progression and longer-term complications, including emerging antiviral drugs, immune-modulating agents, and antibody-based therapies, and the challenges of developing randomized trials to rapidly evaluate the safety and efficacy of each. Peter S. Kim, MD; Sarah W. Read, MD, MHS; Anthony S. Fauci, MD
See More About
Select your interests.
Customize your JAMA Network experience by selecting one or more topics from the list below.
- Academic Medicine
- Acid Base, Electrolytes, Fluids
- Allergy and Clinical Immunology
- American Indian or Alaska Natives
- Anesthesiology
- Anticoagulation
- Art and Images in Psychiatry
- Artificial Intelligence
- Assisted Reproduction
- Bleeding and Transfusion
- Caring for the Critically Ill Patient
- Challenges in Clinical Electrocardiography
- Climate and Health
- Climate Change
- Clinical Challenge
- Clinical Decision Support
- Clinical Implications of Basic Neuroscience
- Clinical Pharmacy and Pharmacology
- Complementary and Alternative Medicine
- Consensus Statements
- Coronavirus (COVID-19)
- Critical Care Medicine
- Cultural Competency
- Dental Medicine
- Dermatology
- Diabetes and Endocrinology
- Diagnostic Test Interpretation
- Digital Health
- Drug Development
- Electronic Health Records
- Emergency Medicine
- End of Life, Hospice, Palliative Care
- Environmental Health
- Equity, Diversity, and Inclusion
- Facial Plastic Surgery
- Gastroenterology and Hepatology
- Genetics and Genomics
- Genomics and Precision Health
- Global Health
- Guide to Statistics and Methods
- Hair Disorders
- Health Care Delivery Models
- Health Care Economics, Insurance, Payment
- Health Care Quality
- Health Care Reform
- Health Care Safety
- Health Care Workforce
- Health Disparities
- Health Inequities
- Health Policy
- Health Systems Science
- History of Medicine
- Hypertension
- Images in Neurology
- Implementation Science
- Infectious Diseases
- Innovations in Health Care Delivery
- JAMA Infographic
- Law and Medicine
- Leading Change
- Less is More
- LGBTQIA Medicine
- Lifestyle Behaviors
- Medical Coding
- Medical Devices and Equipment
- Medical Education
- Medical Education and Training
- Medical Journals and Publishing
- Mobile Health and Telemedicine
- Narrative Medicine
- Neuroscience and Psychiatry
- Notable Notes
- Nutrition, Obesity, Exercise
- Obstetrics and Gynecology
- Occupational Health
- Ophthalmology
- Orthopedics
- Otolaryngology
- Pain Medicine
- Palliative Care
- Pathology and Laboratory Medicine
- Patient Care
- Patient Information
- Performance Improvement
- Performance Measures
- Perioperative Care and Consultation
- Pharmacoeconomics
- Pharmacoepidemiology
- Pharmacogenetics
- Pharmacy and Clinical Pharmacology
- Physical Medicine and Rehabilitation
- Physical Therapy
- Physician Leadership
- Population Health
- Primary Care
- Professional Well-being
- Professionalism
- Psychiatry and Behavioral Health
- Public Health
- Pulmonary Medicine
- Regulatory Agencies
- Reproductive Health
- Research, Methods, Statistics
- Resuscitation
- Rheumatology
- Risk Management
- Scientific Discovery and the Future of Medicine
- Sexual Health
- Shared Decision Making and Communication
- Sleep Medicine
- Sports Medicine
- Stem Cell Transplantation
- Substance Use and Addiction Medicine
- Surgical Innovation
- Surgical Pearls
- Teachable Moment
- Technology and Finance
- The Art of JAMA
- The Arts and Medicine
- The Rational Clinical Examination
- Tobacco and e-Cigarettes
- Translational Medicine
- Trauma and Injury
- Treatment Adherence
- Ultrasonography
- Users' Guide to the Medical Literature
- Vaccination
- Venous Thromboembolism
- Veterans Health
- Women's Health
- Workflow and Process
- Wound Care, Infection, Healing
Others Also Liked
- Download PDF
- X Facebook More LinkedIn
Wiersinga WJ , Rhodes A , Cheng AC , Peacock SJ , Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) : A Review . JAMA. 2020;324(8):782–793. doi:10.1001/jama.2020.12839
Manage citations:
© 2024
- Permissions
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) : A Review
- 1 Division of Infectious Diseases, Department of Medicine, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands
- 2 Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands
- 3 Department of Intensive Care Medicine, St George's University Hospitals Foundation Trust, London, United Kingdom
- 4 Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, Australia
- 5 School of Public Health and Preventive Medicine, Monash University, Monash University, Melbourne, Australia
- 6 National Infection Service, Public Health England, London, United Kingdom
- 7 Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom
- 8 Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor
- 9 VA Center for Clinical Management Research, Ann Arbor, Michigan
- Review Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) James M. Sanders, PhD, PharmD; Marguerite L. Monogue, PharmD; Tomasz Z. Jodlowski, PharmD; James B. Cutrell, MD JAMA
- Viewpoint Ensuring Scientific Integrity and Public Confidence in the Search for Effective COVID-19 Treatment Jesse L. Goodman, MD, MPH; Luciana Borio, MD JAMA
- Viewpoint Monoclonal Antibodies for Prevention and Treatment of COVID-19 Mary Marovich, MD; John R. Mascola, MD; Myron S. Cohen, MD JAMA
- Preliminary Communication Presence of Genetic Variants Among Young Men With Severe COVID-19 Caspar I. van der Made, MD; Annet Simons, PhD; Janneke Schuurs-Hoeijmakers, MD, PhD; Guus van den Heuvel, MD; Tuomo Mantere, PhD; Simone Kersten, MSc; Rosanne C. van Deuren, MSc; Marloes Steehouwer, BSc; Simon V. van Reijmersdal, BSc; Martin Jaeger, PhD; Tom Hofste, BSc; Galuh Astuti, PhD; Jordi Corominas Galbany, PhD; Vyne van der Schoot, MD, PhD; Hans van der Hoeven, MD, PhD; Wanda Hagmolen of ten Have, MD, PhD; Eva Klijn, MD, PhD; Catrien van den Meer, MD; Jeroen Fiddelaers, MD; Quirijn de Mast, MD, PhD; Chantal P. Bleeker-Rovers, MD, PhD; Leo A. B. Joosten, PhD; Helger G. Yntema, PhD; Christian Gilissen, PhD; Marcel Nelen, PhD; Jos W. M. van der Meer, MD, PhD; Han G. Brunner, MD, PhD; Mihai G. Netea, MD, PhD; Frank L. van de Veerdonk, MD, PhD; Alexander Hoischen, PhD JAMA
- Viewpoint Strongyloides Hyperinfection Risk in COVID-19 Patients Treated With Dexamethasone William M. Stauffer, MD, MSPH; Jonathan D. Alpern, MD; Patricia F. Walker, MD, DTM&H JAMA
- JAMA Patient Page Patient Information: COVID-19 W. Joost Wiersinga, MD, PhD, MBA; Hallie C. Prescott, MD, MSc JAMA
- Research Letter Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions Matthijs Kox, PhD; Nicole J. B. Waalders, BSc; Emma J. Kooistra, BSc; Jelle Gerretsen, BSc; Peter Pickkers, MD, PhD JAMA
- Research Letter Racial/Ethnic Variation in Nasal Transmembrane Serine Protease 2 ( TMPRSS2 ) Gene Expression Facilitating Coronavirus Entry Supinda Bunyavanich, MD, MPH, MPhil; Chantal Grant, MD; Alfin Vicencio, MD JAMA
- Viewpoint Therapy for Early COVID-19—A Critical Need Peter S. Kim, MD; Sarah W. Read, MD, MHS; Anthony S. Fauci, MD JAMA
Importance The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19.
Observations SARS-CoV-2 is spread primarily via respiratory droplets during close face-to-face contact. Infection can be spread by asymptomatic, presymptomatic, and symptomatic carriers. The average time from exposure to symptom onset is 5 days, and 97.5% of people who develop symptoms do so within 11.5 days. The most common symptoms are fever, dry cough, and shortness of breath. Radiographic and laboratory abnormalities, such as lymphopenia and elevated lactate dehydrogenase, are common, but nonspecific. Diagnosis is made by detection of SARS-CoV-2 via reverse transcription polymerase chain reaction testing, although false-negative test results may occur in up to 20% to 67% of patients; however, this is dependent on the quality and timing of testing. Manifestations of COVID-19 include asymptomatic carriers and fulminant disease characterized by sepsis and acute respiratory failure. Approximately 5% of patients with COVID-19, and 20% of those hospitalized, experience severe symptoms necessitating intensive care. More than 75% of patients hospitalized with COVID-19 require supplemental oxygen. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care (21.6% vs 24.6%; age-adjusted rate ratio, 0.83 [95% CI, 0.74-0.92]) and that remdesivir improves time to recovery (hospital discharge or no supplemental oxygen requirement) from 15 to 11 days. In a randomized trial of 103 patients with COVID-19, convalescent plasma did not shorten time to recovery. Ongoing trials are testing antiviral therapies, immune modulators, and anticoagulants. The case-fatality rate for COVID-19 varies markedly by age, ranging from 0.3 deaths per 1000 cases among patients aged 5 to 17 years to 304.9 deaths per 1000 cases among patients aged 85 years or older in the US. Among patients hospitalized in the intensive care unit, the case fatality is up to 40%. At least 120 SARS-CoV-2 vaccines are under development. Until an effective vaccine is available, the primary methods to reduce spread are face masks, social distancing, and contact tracing. Monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies.
Conclusions and Relevance As of July 1, 2020, more than 10 million people worldwide had been infected with SARS-CoV-2. Many aspects of transmission, infection, and treatment remain unclear. Advances in prevention and effective management of COVID-19 will require basic and clinical investigation and public health and clinical interventions.
The coronavirus disease 2019 (COVID-19) pandemic has caused a sudden significant increase in hospitalizations for pneumonia with multiorgan disease. COVID-19 is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection may be asymptomatic or it may cause a wide spectrum of symptoms, such as mild symptoms of upper respiratory tract infection and life-threatening sepsis. COVID-19 first emerged in December 2019, when a cluster of patients with pneumonia of unknown cause was recognized in Wuhan, China. As of July 1, 2020, SARS-CoV-2 has affected more than 200 countries, resulting in more than 10 million identified cases with 508 000 confirmed deaths ( Figure 1 ). This review summarizes current evidence regarding pathophysiology, transmission, diagnosis, and management of COVID-19.
We searched PubMed, LitCovid, and MedRxiv using the search terms coronavirus , severe acute respiratory syndrome coronavirus 2 , 2019-nCoV , SARS-CoV-2 , SARS-CoV , MERS-CoV , and COVID-19 for studies published from January 1, 2002, to June 15, 2020, and manually searched the references of select articles for additional relevant articles. Ongoing or completed clinical trials were identified using the disease search term coronavirus infection on ClinicalTrials.gov, the Chinese Clinical Trial Registry, and the International Clinical Trials Registry Platform. We selected articles relevant to a general medicine readership, prioritizing randomized clinical trials, systematic reviews, and clinical practice guidelines.
Coronaviruses are large, enveloped, single-stranded RNA viruses found in humans and other mammals, such as dogs, cats, chicken, cattle, pigs, and birds. Coronaviruses cause respiratory, gastrointestinal, and neurological disease. The most common coronaviruses in clinical practice are 229E, OC43, NL63, and HKU1, which typically cause common cold symptoms in immunocompetent individuals. SARS-CoV-2 is the third coronavirus that has caused severe disease in humans to spread globally in the past 2 decades. 1 The first coronavirus that caused severe disease was severe acute respiratory syndrome (SARS), which was thought to originate in Foshan, China, and resulted in the 2002-2003 SARS-CoV pandemic. 2 The second was the coronavirus-caused Middle East respiratory syndrome (MERS), which originated from the Arabian peninsula in 2012. 3
SARS-CoV-2 has a diameter of 60 nm to 140 nm and distinctive spikes, ranging from 9 nm to 12 nm, giving the virions the appearance of a solar corona ( Figure 2 ). 4 Through genetic recombination and variation, coronaviruses can adapt to and infect new hosts. Bats are thought to be a natural reservoir for SARS-CoV-2, but it has been suggested that humans became infected with SARS-CoV-2 via an intermediate host, such as the pangolin. 5 , 6
Early in infection, SARS-CoV-2 targets cells, such as nasal and bronchial epithelial cells and pneumocytes, through the viral structural spike (S) protein that binds to the angiotensin-converting enzyme 2 (ACE2) receptor 7 ( Figure 2 ). The type 2 transmembrane serine protease (TMPRSS2), present in the host cell, promotes viral uptake by cleaving ACE2 and activating the SARS-CoV-2 S protein, which mediates coronavirus entry into host cells. 7 ACE2 and TMPRSS2 are expressed in host target cells, particularly alveolar epithelial type II cells. 8 , 9 Similar to other respiratory viral diseases, such as influenza, profound lymphopenia may occur in individuals with COVID-19 when SARS-CoV-2 infects and kills T lymphocyte cells. In addition, the viral inflammatory response, consisting of both the innate and the adaptive immune response (comprising humoral and cell-mediated immunity), impairs lymphopoiesis and increases lymphocyte apoptosis. Although upregulation of ACE2 receptors from ACE inhibitor and angiotensin receptor blocker medications has been hypothesized to increase susceptibility to SARS-CoV-2 infection, large observational cohorts have not found an association between these medications and risk of infection or hospital mortality due to COVID-19. 10 , 11 For example, in a study 4480 patients with COVID-19 from Denmark, previous treatment with ACE inhibitors or angiotensin receptor blockers was not associated with mortality. 11
In later stages of infection, when viral replication accelerates, epithelial-endothelial barrier integrity is compromised. In addition to epithelial cells, SARS-CoV-2 infects pulmonary capillary endothelial cells, accentuating the inflammatory response and triggering an influx of monocytes and neutrophils. Autopsy studies have shown diffuse thickening of the alveolar wall with mononuclear cells and macrophages infiltrating airspaces in addition to endothelialitis. 12 Interstitial mononuclear inflammatory infiltrates and edema develop and appear as ground-glass opacities on computed tomographic imaging. Pulmonary edema filling the alveolar spaces with hyaline membrane formation follows, compatible with early-phase acute respiratory distress syndrome (ARDS). 12 Bradykinin-dependent lung angioedema may contribute to disease. 13 Collectively, endothelial barrier disruption, dysfunctional alveolar-capillary oxygen transmission, and impaired oxygen diffusion capacity are characteristic features of COVID-19.
In severe COVID-19, fulminant activation of coagulation and consumption of clotting factors occur. 14 , 15 A report from Wuhan, China, indicated that 71% of 183 individuals who died of COVID-19 met criteria for diffuse intravascular coagulation. 14 Inflamed lung tissues and pulmonary endothelial cells may result in microthrombi formation and contribute to the high incidence of thrombotic complications, such as deep venous thrombosis, pulmonary embolism, and thrombotic arterial complications (eg, limb ischemia, ischemic stroke, myocardial infarction) in critically ill patients. 16 The development of viral sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, may further contribute to multiorgan failure.
Epidemiologic data suggest that droplets expelled during face-to-face exposure during talking, coughing, or sneezing is the most common mode of transmission ( Box 1 ). Prolonged exposure to an infected person (being within 6 feet for at least 15 minutes) and briefer exposures to individuals who are symptomatic (eg, coughing) are associated with higher risk for transmission, while brief exposures to asymptomatic contacts are less likely to result in transmission. 25 Contact surface spread (touching a surface with virus on it) is another possible mode of transmission. Transmission may also occur via aerosols (smaller droplets that remain suspended in air), but it is unclear if this is a significant source of infection in humans outside of a laboratory setting. 26 , 27 The existence of aerosols in physiological states (eg, coughing) or the detection of nucleic acid in the air does not mean that small airborne particles are infectious. 28 Maternal COVID-19 is currently believed to be associated with low risk for vertical transmission. In most reported series, the mothers' infection with SARS-CoV-2 occurred in the third trimester of pregnancy, with no maternal deaths and a favorable clinical course in the neonates. 29 - 31
Transmission, Symptoms, and Complications of Coronavirus Disease 2019 (COVID-19)
Transmission 17 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs primarily via respiratory droplets from face-to-face contact and, to a lesser degree, via contaminated surfaces. Aerosol spread may occur, but the role of aerosol spread in humans remains unclear. An estimated 48% to 62% of transmission may occur via presymptomatic carriers.
Common symptoms 18 in hospitalized patients include fever (70%-90%), dry cough (60%-86%), shortness of breath (53%-80%), fatigue (38%), myalgias (15%-44%), nausea/vomiting or diarrhea (15%-39%), headache, weakness (25%), and rhinorrhea (7%). Anosmia or ageusia may be the sole presenting symptom in approximately 3% of individuals with COVID-19.
Common laboratory abnormalities 19 among hospitalized patients include lymphopenia (83%), elevated inflammatory markers (eg, erythrocyte sedimentation rate, C-reactive protein, ferritin, tumor necrosis factor-α, IL-1, IL-6), and abnormal coagulation parameters (eg, prolonged prothrombin time, thrombocytopenia, elevated D-dimer [46% of patients], low fibrinogen).
Common radiographic findings of individuals with COVID-19 include bilateral, lower-lobe predominate infiltrates on chest radiographic imaging and bilateral, peripheral, lower-lobe ground-glass opacities and/or consolidation on chest computed tomographic imaging.
Common complications 18 , 20 - 24 among hospitalized patients with COVID-19 include pneumonia (75%); acute respiratory distress syndrome (15%); acute liver injury, characterized by elevations in aspartate transaminase, alanine transaminase, and bilirubin (19%); cardiac injury, including troponin elevation (7%-17%), acute heart failure, dysrhythmias, and myocarditis; prothrombotic coagulopathy resulting in venous and arterial thromboembolic events (10%-25%); acute kidney injury (9%); neurologic manifestations, including impaired consciousness (8%) and acute cerebrovascular disease (3%); and shock (6%).
Rare complications among critically ill patients with COVID-19 include cytokine storm and macrophage activation syndrome (ie, secondary hemophagocytic lymphohistiocytosis).
The clinical significance of SARS-CoV-2 transmission from inanimate surfaces is difficult to interpret without knowing the minimum dose of virus particles that can initiate infection. Viral load appears to persist at higher levels on impermeable surfaces, such as stainless steel and plastic, than permeable surfaces, such as cardboard. 32 Virus has been identified on impermeable surfaces for up to 3 to 4 days after inoculation. 32 Widespread viral contamination of hospital rooms has been documented. 28 However, it is thought that the amount of virus detected on surfaces decays rapidly within 48 to 72 hours. 32 Although the detection of virus on surfaces reinforces the potential for transmission via fomites (objects such as a doorknob, cutlery, or clothing that may be contaminated with SARS-CoV-2) and the need for adequate environmental hygiene, droplet spread via face-to-face contact remains the primary mode of transmission.
Viral load in the upper respiratory tract appears to peak around the time of symptom onset and viral shedding begins approximately 2 to 3 days prior to the onset of symptoms. 33 Asymptomatic and presymptomatic carriers can transmit SARS-CoV-2. 34 , 35 In Singapore, presymptomatic transmission has been described in clusters of patients with close contact (eg, through churchgoing or singing class) approximately 1 to 3 days before the source patient developed symptoms. 34 Presymptomatic transmission is thought to be a major contributor to the spread of SARS-CoV-2. Modeling studies from China and Singapore estimated the percentage of infections transmitted from a presymptomatic individual as 48% to 62%. 17 Pharyngeal shedding is high during the first week of infection at a time in which symptoms are still mild, which might explain the efficient transmission of SARS-CoV-2, because infected individuals can be infectious before they realize they are ill. 36 Although studies have described rates of asymptomatic infection, ranging from 4% to 32%, it is unclear whether these reports represent truly asymptomatic infection by individuals who never develop symptoms, transmission by individuals with very mild symptoms, or transmission by individuals who are asymptomatic at the time of transmission but subsequently develop symptoms. 37 - 39 A systematic review on this topic suggested that true asymptomatic infection is probably uncommon. 38
Although viral nucleic acid can be detectable in throat swabs for up to 6 weeks after the onset of illness, several studies suggest that viral cultures are generally negative for SARS-CoV-2 8 days after symptom onset. 33 , 36 , 40 This is supported by epidemiological studies that have shown that transmission did not occur to contacts whose exposure to the index case started more than 5 days after the onset of symptoms in the index case. 41 This suggests that individuals can be released from isolation based on clinical improvement. The Centers for Disease Control and Prevention recommend isolating for at least 10 days after symptom onset and 3 days after improvement of symptoms. 42 However, there remains uncertainty about whether serial testing is required for specific subgroups, such as immunosuppressed patients or critically ill patients for whom symptom resolution may be delayed or older adults residing in short- or long-term care facilities.
The mean (interquartile range) incubation period (the time from exposure to symptom onset) for COVID-19 is approximately 5 (2-7) days. 43 , 44 Approximately 97.5% of individuals who develop symptoms will do so within 11.5 days of infection. 43 The median (interquartile range) interval from symptom onset to hospital admission is 7 (3-9) days. 45 The median age of hospitalized patients varies between 47 and 73 years, with most cohorts having a male preponderance of approximately 60%. 44 , 46 , 47 Among patients hospitalized with COVID-19, 74% to 86% are aged at least 50 years. 45 , 47
COVID-19 has various clinical manifestations ( Box 1 and Box 2 ). In a study of 44 672 patients with COVID-19 in China, 81% of patients had mild manifestations, 14% had severe manifestations, and 5% had critical manifestations (defined by respiratory failure, septic shock, and/or multiple organ dysfunction). 48 A study of 20 133 individuals hospitalized with COVID-19 in the UK reported that 17.1% were admitted to high-dependency or intensive care units (ICUs). 47
Commonly Asked Questions About Coronavirus Disease 2019 (COVID-19)
How is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) most commonly transmitted?
SARS-CoV-2 is most commonly spread via respiratory droplets (eg, from coughing, sneezing, shouting) during face-to-face exposure or by surface contamination.
What are the most common symptoms of COVID-19?
The 3 most common symptoms are fever, cough, and shortness of breath. Additional symptoms include weakness, fatigue, nausea, vomiting, diarrhea, changes to taste and smell.
How is the diagnosis made?
Diagnosis of COVID-19 is typically made by polymerase chain reaction testing of a nasopharyngeal swab. However, given the possibility of false-negative test results, clinical, laboratory, and imaging findings may also be used to make a presumptive diagnosis for individuals for whom there is a high index of clinical suspicion of infection.
What are current evidence-based treatments for individuals with COVID-19?
Supportive care, including supplemental oxygen, is the main treatment for most patients. Recent trials indicate that dexamethasone decreases mortality (subgroup analysis suggests benefit is limited to patients who require supplemental oxygen and who have symptoms for >7 d) and remdesivir improves time to recovery (subgroup analysis suggests benefit is limited to patients not receiving mechanical ventilation).
What percentage of people are asymptomatic carriers, and how important are they in transmitting the disease?
True asymptomatic infection is believed to be uncommon. The average time from exposure to symptoms onset is 5 days, and up to 62% of transmission may occur prior to the onset of symptoms.
Are masks effective at preventing spread?
Yes. Face masks reduce the spread of viral respiratory infection. N95 respirators and surgical masks both provide substantial protection (compared with no mask), and surgical masks provide greater protection than cloth masks. However, physical distancing is also associated with substantial reduction of viral transmission, with greater distances providing greater protection. Additional measures such as hand and environmental disinfection are also important.
Although only approximately 25% of infected patients have comorbidities, 60% to 90% of hospitalized infected patients have comorbidities. 45 - 49 The most common comorbidities in hospitalized patients include hypertension (present in 48%-57% of patients), diabetes (17%-34%), cardiovascular disease (21%-28%), chronic pulmonary disease (4%-10%), chronic kidney disease (3%-13%), malignancy (6%-8%), and chronic liver disease (<5%). 45 , 46 , 49
The most common symptoms in hospitalized patients are fever (up to 90% of patients), dry cough (60%-86%), shortness of breath (53%-80%), fatigue (38%), nausea/vomiting or diarrhea (15%-39%), and myalgia (15%-44%). 18 , 44 - 47 , 49 , 50 Patients can also present with nonclassical symptoms, such as isolated gastrointestinal symptoms. 18 Olfactory and/or gustatory dysfunctions have been reported in 64% to 80% of patients. 51 - 53 Anosmia or ageusia may be the sole presenting symptom in approximately 3% of patients. 53
Complications of COVID-19 include impaired function of the heart, brain, lung, liver, kidney, and coagulation system. COVID-19 can lead to myocarditis, cardiomyopathy, ventricular arrhythmias, and hemodynamic instability. 20 , 54 Acute cerebrovascular disease and encephalitis are observed with severe illness (in up to 8% of patients). 21 , 52 Venous and arterial thromboembolic events occur in 10% to 25% in hospitalized patients with COVID-19. 19 , 22 In the ICU, venous and arterial thromboembolic events may occur in up to 31% to 59% of patients with COVID-19. 16 , 22
Approximately 17% to 35% of hospitalized patients with COVID-19 are treated in an ICU, most commonly due to hypoxemic respiratory failure. Among patients in the ICU with COVID-19, 29% to 91% require invasive mechanical ventilation. 47 , 49 , 55 , 56 In addition to respiratory failure, hospitalized patients may develop acute kidney injury (9%), liver dysfunction (19%), bleeding and coagulation dysfunction (10%-25%), and septic shock (6%). 18 , 19 , 23 , 49 , 56
Approximately 2% to 5% of individuals with laboratory-confirmed COVID-19 are younger than 18 years, with a median age of 11 years. Children with COVID-19 have milder symptoms that are predominantly limited to the upper respiratory tract, and rarely require hospitalization. It is unclear why children are less susceptible to COVID-19. Potential explanations include that children have less robust immune responses (ie, no cytokine storm), partial immunity from other viral exposures, and lower rates of exposure to SARS-CoV-2. Although most pediatric cases are mild, a small percentage (<7%) of children admitted to the hospital for COVID-19 develop severe disease requiring mechanical ventilation. 57 A rare multisystem inflammatory syndrome similar to Kawasaki disease has recently been described in children in Europe and North America with SARS-CoV-2 infection. 58 , 59 This multisystem inflammatory syndrome in children is uncommon (2 in 100 000 persons aged <21 years). 60
Diagnosis of COVID-19 is typically made using polymerase chain reaction testing via nasal swab ( Box 2 ). However, because of false-negative test result rates of SARS-CoV-2 PCR testing of nasal swabs, clinical, laboratory, and imaging findings may also be used to make a presumptive diagnosis.
Reverse transcription polymerase chain reaction–based SARS-CoV-2 RNA detection from respiratory samples (eg, nasopharynx) is the standard for diagnosis. However, the sensitivity of testing varies with timing of testing relative to exposure. One modeling study estimated sensitivity at 33% 4 days after exposure, 62% on the day of symptom onset, and 80% 3 days after symptom onset. 61 - 63 Factors contributing to false-negative test results include the adequacy of the specimen collection technique, time from exposure, and specimen source. Lower respiratory samples, such as bronchoalveolar lavage fluid, are more sensitive than upper respiratory samples. Among 1070 specimens collected from 205 patients with COVID-19 in China, bronchoalveolar lavage fluid specimens had the highest positive rates of SARS-CoV-2 PCR testing results (93%), followed by sputum (72%), nasal swabs (63%), and pharyngeal swabs (32%). 61 SARS-CoV-2 can also be detected in feces, but not in urine. 61 Saliva may be an alternative specimen source that requires less personal protective equipment and fewer swabs, but requires further validation. 64
Several serological tests can also aid in the diagnosis and measurement of responses to novel vaccines. 62 , 65 , 66 However, the presence of antibodies may not confer immunity because not all antibodies produced in response to infection are neutralizing. Whether and how frequently second infections with SARS-CoV-2 occur remain unknown. Whether presence of antibody changes susceptibility to subsequent infection or how long antibody protection lasts are unknown. IgM antibodies are detectable within 5 days of infection, with higher IgM levels during weeks 2 to 3 of illness, while an IgG response is first seen approximately 14 days after symptom onset. 62 , 65 Higher antibody titers occur with more severe disease. 66 Available serological assays include point-of-care assays and high throughput enzyme immunoassays. However, test performance, accuracy, and validity are variable. 67
A systematic review of 19 studies of 2874 patients who were mostly from China (mean age, 52 years), of whom 88% were hospitalized, reported the typical range of laboratory abnormalities seen in COVID-19, including elevated serum C-reactive protein (increased in >60% of patients), lactate dehydrogenase (increased in approximately 50%-60%), alanine aminotransferase (elevated in approximately 25%), and aspartate aminotransferase (approximately 33%). 24 Approximately 75% of patients had low albumin. 24 The most common hematological abnormality is lymphopenia (absolute lymphocyte count <1.0 × 10 9 /L), which is present in up to 83% of hospitalized patients with COVID-19. 44 , 50 In conjunction with coagulopathy, modest prolongation of prothrombin times (prolonged in >5% of patients), mild thrombocytopenia (present in approximately 30% of patients) and elevated D-dimer values (present in 43%-60% of patients) are common. 14 , 15 , 19 , 44 , 68 However, most of these laboratory characteristics are nonspecific and are common in pneumonia. More severe laboratory abnormalities have been associated with more severe infection. 44 , 50 , 69 D-dimer and, to a lesser extent, lymphopenia seem to have the largest prognostic associations. 69
The characteristic chest computed tomographic imaging abnormalities for COVID-19 are diffuse, peripheral ground-glass opacities ( Figure 3 ). 70 Ground-glass opacities have ill-defined margins, air bronchograms, smooth or irregular interlobular or septal thickening, and thickening of the adjacent pleura. 70 Early in the disease, chest computed tomographic imaging findings in approximately 15% of individuals and chest radiograph findings in approximately 40% of individuals can be normal. 44 Rapid evolution of abnormalities can occur in the first 2 weeks after symptom onset, after which they subside gradually. 70 , 71
Chest computed tomographic imaging findings are nonspecific and overlap with other infections, so the diagnostic value of chest computed tomographic imaging for COVID-19 is limited. Some patients admitted to the hospital with polymerase chain reaction testing–confirmed SARS-CoV-2 infection have normal computed tomographic imaging findings, while abnormal chest computed tomographic imaging findings compatible with COVID-19 occur days before detection of SARS-CoV-2 RNA in other patients. 70 , 71
Currently, best practices for supportive management of acute hypoxic respiratory failure and ARDS should be followed. 72 - 74 Evidence-based guideline initiatives have been established by many countries and professional societies, 72 - 74 including guidelines that are updated regularly by the National Institutes of Health. 74
More than 75% of patients hospitalized with COVID-19 require supplemental oxygen therapy. For patients who are unresponsive to conventional oxygen therapy, heated high-flow nasal canula oxygen may be administered. 72 For patients requiring invasive mechanical ventilation, lung-protective ventilation with low tidal volumes (4-8 mL/kg, predicted body weight) and plateau pressure less than 30 mg Hg is recommended. 72 Additionally, prone positioning, a higher positive end-expiratory pressure strategy, and short-term neuromuscular blockade with cisatracurium or other muscle relaxants may facilitate oxygenation. Although some patients with COVID-19–related respiratory failure have high lung compliance, 75 they are still likely to benefit from lung-protective ventilation. 76 Cohorts of patients with ARDS have displayed similar heterogeneity in lung compliance, and even patients with greater compliance have shown benefit from lower tidal volume strategies. 76
The threshold for intubation in COVID-19–related respiratory failure is controversial, because many patients have normal work of breathing but severe hypoxemia. 77 “Earlier” intubation allows time for a more controlled intubation process, which is important given the logistical challenges of moving patients to an airborne isolation room and donning personal protective equipment prior to intubation. However, hypoxemia in the absence of respiratory distress is well tolerated, and patients may do well without mechanical ventilation. Earlier intubation thresholds may result in treating some patients with mechanical ventilation unnecessarily and exposing them to additional complications. Currently, insufficient evidence exists to make recommendations regarding earlier vs later intubation.
In observational studies, approximately 8% of hospitalized patients with COVID-19 experience a bacterial or fungal co-infection, but up to 72% are treated with broad-spectrum antibiotics. 78 Awaiting further data, it may be prudent to withhold antibacterial drugs in patients with COVID-19 and reserve them for those who present with radiological findings and/or inflammatory markers compatible with co-infection or who are immunocompromised and/or critically ill. 72
The following classes of drugs are being evaluated or developed for the management of COVID-19: antivirals (eg, remdesivir, favipiravir), antibodies (eg, convalescent plasma, hyperimmune immunoglobulins), anti-inflammatory agents (dexamethasone, statins), targeted immunomodulatory therapies (eg, tocilizumab, sarilumab, anakinra, ruxolitinib), anticoagulants (eg, heparin), and antifibrotics (eg, tyrosine kinase inhibitors). It is likely that different treatment modalities might have different efficacies at different stages of illness and in different manifestations of disease. Viral inhibition would be expected to be most effective early in infection, while, in hospitalized patients, immunomodulatory agents may be useful to prevent disease progression and anticoagulants may be useful to prevent thromboembolic complications.
More than 200 trials of chloroquine/hydroxychloroquine, compounds that inhibit viral entry and endocytosis of SARS-CoV-2 in vitro and may have beneficial immunomodulatory effects in vivo, 79 , 80 have been initiated, but early data from clinical trials in hospitalized patients with COVID-19 have not demonstrated clear benefit. 81 - 83 A clinical trial of 150 patients in China admitted to the hospital for mild to moderate COVID-19 did not find an effect on negative conversion of SARS-CoV-2 by 28 days (the main outcome measure) when compared with standard of care alone. 83 Two retrospective studies found no effect of hydroxychloroquine on risk of intubation or mortality among patients hospitalized for COVID-19. 84 , 85 One of these retrospective multicenter cohort studies compared in-hospital mortality between those treated with hydroxychloroquine plus azithromycin (735 patients), hydroxychloroquine alone (271 patients), azithromycin alone (211 patients), and neither drug (221 patients), but reported no differences across the groups. 84 Adverse effects are common, most notably QT prolongation with an increased risk of cardiac complications in an already vulnerable population. 82 , 84 These findings do not support off-label use of (hydroxy)chloroquine either with or without the coadministration of azithromycin. Randomized clinical trials are ongoing and should provide more guidance.
Most antiviral drugs undergoing clinical testing in patients with COVID-19 are repurposed antiviral agents originally developed against influenza, HIV, Ebola, or SARS/MERS. 79 , 86 Use of the protease inhibitor lopinavir-ritonavir, which disrupts viral replication in vitro, did not show benefit when compared with standard care in a randomized, controlled, open-label trial of 199 hospitalized adult patients with severe COVID-19. 87 Among the RNA-dependent RNA polymerase inhibitors, which halt SARS-CoV-2 replication, being evaluated, including ribavirin, favipiravir, and remdesivir, the latter seems to be the most promising. 79 , 88 The first preliminary results of a double-blind, randomized, placebo-controlled trial of 1063 adults hospitalized with COVID-19 and evidence of lower respiratory tract involvement who were randomly assigned to receive intravenous remdesivir or placebo for up to 10 days demonstrated that patients randomized to receive remdesivir had a shorter time to recovery than patients in the placebo group (11 vs 15 days). 88 A separate randomized, open-label trial among 397 hospitalized patients with COVID-19 who did not require mechanical ventilation reported that 5 days of treatment with remdesivir was not different than 10 days in terms of clinical status on day 14. 89 The effect of remdesivir on survival remains unknown.
Treatment with plasma obtained from patients who have recovered from viral infections was first reported during the 1918 flu pandemic. A first report of 5 critically ill patients with COVID-19 treated with convalescent plasma containing neutralizing antibody showed improvement in clinical status among all participants, defined as a combination of changes of body temperature, Sequential Organ Failure Assessment score, partial pressure of oxygen/fraction of inspired oxygen, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation supports before and after convalescent plasma transfusion status. 90 However, a subsequent multicenter, open-label, randomized clinical trial of 103 patients in China with severe COVID-19 found no statistical difference in time to clinical improvement within 28 days among patients randomized to receive convalescent plasma vs standard treatment alone (51.9% vs 43.1%). 91 However, the trial was stopped early because of slowing enrollment, which limited the power to detect a clinically important difference. Alternative approaches being studied include the use of convalescent plasma-derived hyperimmune globulin and monoclonal antibodies targeting SARS-CoV-2. 92 , 93
Alternative therapeutic strategies consist of modulating the inflammatory response in patients with COVID-19. Monoclonal antibodies directed against key inflammatory mediators, such as interferon gamma, interleukin 1, interleukin 6, and complement factor 5a, all target the overwhelming inflammatory response following SARS-CoV-2 infection with the goal of preventing organ damage. 79 , 86 , 94 Of these, the interleukin 6 inhibitors tocilizumab and sarilumab are best studied, with more than a dozen randomized clinical trials underway. 94 Tyrosine kinase inhibitors, such as imatinib, are studied for their potential to prevent pulmonary vascular leakage in individuals with COVID-19.
Studies of corticosteroids for viral pneumonia and ARDS have yielded mixed results. 72 , 73 However, the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, which randomized 2104 patients with COVID-19 to receive 6 mg daily of dexamethasone for up to 10 days and 4321 to receive usual care, found that dexamethasone reduced 28-day all-cause mortality (21.6% vs 24.6%; age-adjusted rate ratio, 0.83 [95% CI, 0.74-0.92]; P < .001). 95 The benefit was greatest in patients with symptoms for more than 7 days and patients who required mechanical ventilation. By contrast, there was no benefit (and possibility for harm) among patients with shorter symptom duration and no supplemental oxygen requirement. A retrospective cohort study of 201 patients in Wuhan, China, with confirmed COVID-19 pneumonia and ARDS reported that treatment with methylprednisolone was associated with reduced risk of death (hazard ratio, 0.38 [95% CI, 0.20-0.72]). 69
Thromboembolic prophylaxis with subcutaneous low molecular weight heparin is recommended for all hospitalized patients with COVID-19. 15 , 19 Studies are ongoing to assess whether certain patients (ie, those with elevated D-dimer) benefit from therapeutic anticoagulation.
A disproportionate percentage of COVID-19 hospitalizations and deaths occurs in lower-income and minority populations. 45 , 96 , 97 In a report by the Centers for Disease Control and Prevention of 580 hospitalized patients for whom race data were available, 33% were Black and 45% were White, while 18% of residents in the surrounding community were Black and 59% were White. 45 The disproportionate prevalence of COVID-19 among Black patients was separately reported in a retrospective cohort study of 3626 patients with COVID-19 from Louisiana, in which 77% of patients hospitalized with COVID-19 and 71% of patients who died of COVID-19 were Black, but Black individuals comprised only 31% of the area population. 97 , 98 This disproportionate burden may be a reflection of disparities in housing, transportation, employment, and health. Minority populations are more likely to live in densely populated communities or housing, depend on public transportation, or work in jobs for which telework was not possible (eg, bus driver, food service worker). Black individuals also have a higher prevalence of chronic health conditions than White individuals. 98 , 99
Overall hospital mortality from COVID-19 is approximately 15% to 20%, but up to 40% among patients requiring ICU admission. However, mortality rates vary across cohorts, reflecting differences in the completeness of testing and case identification, variable thresholds for hospitalization, and differences in outcomes. Hospital mortality ranges from less than 5% among patients younger than 40 years to 35% for patients aged 70 to 79 years and greater than 60% for patients aged 80 to 89 years. 46 Estimated overall death rates by age group per 1000 confirmed cases are provided in the Table . Because not all people who die during the pandemic are tested for COVID-19, actual numbers of deaths from COVID-19 are higher than reported numbers.
Although long-term outcomes from COVID-19 are currently unknown, patients with severe illness are likely to suffer substantial sequelae. Survival from sepsis is associated with increased risk for mortality for at least 2 years, new physical disability, new cognitive impairment, and increased vulnerability to recurrent infection and further health deterioration. Similar sequalae are likely to be seen in survivors of severe COVID-19. 100
COVID-19 is a potentially preventable disease. The relationship between the intensity of public health action and the control of transmission is clear from the epidemiology of infection around the world. 25 , 101 , 102 However, because most countries have implemented multiple infection control measures, it is difficult to determine the relative benefit of each. 103 , 104 This question is increasingly important because continued interventions will be required until effective vaccines or treatments become available. In general, these interventions can be divided into those consisting of personal actions (eg, physical distancing, personal hygiene, and use of protective equipment), case and contact identification (eg, test-trace-track-isolate, reactive school or workplace closure), regulatory actions (eg, governmental limits on sizes of gatherings or business capacity; stay-at-home orders; proactive school, workplace, and public transport closure or restriction; cordon sanitaire or internal border closures), and international border measures (eg, border closure or enforced quarantine). A key priority is to identify the combination of measures that minimizes societal and economic disruption while adequately controlling infection. Optimal measures may vary between countries based on resource limitations, geography (eg, island nations and international border measures), population, and political factors (eg, health literacy, trust in government, cultural and linguistic diversity).
The evidence underlying these public health interventions has not changed since the 1918 flu pandemic. 105 Mathematical modeling studies and empirical evidence support that public health interventions, including home quarantine after infection, restricting mass gatherings, travel restrictions, and social distancing, are associated with reduced rates of transmission. 101 , 102 , 106 Risk of resurgence follows when these interventions are lifted.
A human vaccine is currently not available for SARS-CoV-2, but approximately 120 candidates are under development. Approaches include the use of nucleic acids (DNA or RNA), inactivated or live attenuated virus, viral vectors, and recombinant proteins or virus particles. 107 , 108 Challenges to developing an effective vaccine consist of technical barriers (eg, whether S or receptor-binding domain proteins provoke more protective antibodies, prior exposure to adenovirus serotype 5 [which impairs immunogenicity in the viral vector vaccine], need for adjuvant), feasibility of large-scale production and regulation (eg, ensuring safety and effectiveness), and legal barriers (eg, technology transfer and licensure agreements). The SARS-CoV-2 S protein appears to be a promising immunogen for protection, but whether targeting the full-length protein or only the receptor-binding domain is sufficient to prevent transmission remains unclear. 108 Other considerations include the potential duration of immunity and thus the number of vaccine doses needed to confer immunity. 62 , 108 More than a dozen candidate SARS-CoV-2 vaccines are currently being tested in phase 1-3 trials.
Other approaches to prevention are likely to emerge in the coming months, including monoclonal antibodies, hyperimmune globulin, and convalscent titer. If proved effective, these approaches could be used in high-risk individuals, including health care workers, other essential workers, and older adults (particularly those in nursing homes or long-term care facilities).
This review has several limitations. First, information regarding SARS CoV-2 is limited. Second, information provided here is based on current evidence, but may be modified as more information becomes available. Third, few randomized trials have been published to guide management of COVID-19.
As of July 1, 2020, more than 10 million people worldwide had been infected with SARS-CoV-2. Many aspects of transmission, infection, and treatment remain unclear. Advances in prevention and effective management of COVID-19 will require basic and clinical investigation and public health and clinical interventions.
Accepted for Publication: June 30, 2020.
Corresponding Author: W. Joost Wiersinga, MD, PhD, Division of Infectious Diseases, Department of Medicine, Amsterdam UMC, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands ( [email protected] ).
Published Online: July 10, 2020. doi:10.1001/jama.2020.12839
Conflict of Interest Disclosures: Dr Wiersinga is supported by the Netherlands Organisation of Scientific Research outside the submitted work. Dr Prescott reported receiving grants from the US Agency for Healthcare Research and Quality (HCP by R01 HS026725), the National Institutes of Health/National Institute of General Medical Sciences, and the US Department of Veterans Affairs outside the submitted work, being the sepsis physician lead for the Hospital Medicine Safety Continuous Quality Initiative funded by BlueCross/BlueShield of Michigan, and serving on the steering committee for MI-COVID-19, a Michigan statewide registry to improve care for patients with COVID-19 in Michigan. Dr Rhodes reported being the co-chair of the Surviving Sepsis Campaign. Dr Cheng reported being a member of Australian government advisory committees, including those involved in COVID-19. No other disclosures were reported.
Disclaimer: This article does not represent the views of the US Department of Veterans Affairs or the US government. This material is the result of work supported with resources and use of facilities at the Ann Arbor VA Medical Center. The opinions in this article do not necessarily represent those of the Australian government or advisory committees.
- Register for email alerts with links to free full-text articles
- Access PDFs of free articles
- Manage your interests
- Save searches and receive search alerts
IMAGES
VIDEO
COMMENTS
In this overview of systematic reviews, we aimed to summarize and critically appraise systematic reviews of coronavirus disease (COVID-19) in humans that were available at the beginning of the pandemic.
5. Conclusion. This review has collated the 100 most influential COVID-19 papers and assessed trends within them. We have established that in the early phases of a pandemic new and ground-breaking research surfaces regardless of the evidence level and can gain high levels of citation.
There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Introduction. As of November 21st, 2021, over 257 million cases of coronavirus disease 2019 (COVID-19) have been reported, and more than 5 million lives claimed globally [1]. The disease is...
This review summarizes the current state of knowledge about immune responses to Covid-19 vaccines and the importance of both humoral and cellular immunity for durable protection against...
Abstract. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute...
COVID-19, the disease caused by SARS-CoV-2, has caused significant morbidity and mortality worldwide. The betacoronavirus continues to evolve with global health implications as we race to learn...
In this Viewpoint, Fauci and NIAID colleagues review leading candidates for treatment of mild to moderate coronavirus disease 2019 (COVID-19) to prevent disease progression and longer-term complications, including emerging antiviral drugs, immune-modulating agents, and antibody-based therapies, and the challenges of developing randomized trials ...
Explore a collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
Here, we share our view of the current evidence-based consensus on COVID-19. SARS-CoV-2 spreads through contact (via larger droplets and aerosols), and longer-range transmission via aerosols, especially in conditions where ventilation is poor.